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 Leprosy is a chronic granulomatous disease caused by 
Mycobacterium leprae. It is also known as Hansen’s disease since its 
causative agent was first described by a Norwegian physician, Gerhard 
Henrik Armauer Hansen in 1873. Mycobacterium leprae has the 
distinction of being the  first pathogenic organism to be discovered. 
Leprosy as an infection in man could be compared to a peat fire which 
keeps smouldering for a long time but suddenly bursts into flames when 
conditions are favourable, such sudden flares in the course of leprosy are 
referred to as reactional states in leprosy. This thesis is an attempt to 
study the Type I and Type II lepra reactions in detail with special 
reference to the clinical features and histopathology.  
 
REVIEW OF LITERATURE 
Definition : 
 In clinical terms the word reaction is used to describe the 
appearance of symptoms and signs of acute inflammation in lesions of a 
patient with leprosy.  
 In immunological terms, reactions are episodes of acute 
hypersensitivity to bacterial antigens, brought about by a disturbance of 
the pre existing immunological balance. 
Classification : 
 Various authors Muir.E (1948), Cochrane (1964), Dharmendra 
(1967), Madrid Congress (1953), Rio Congress (1963), Jopling W.H 
(1971), Waters M.F.R (1971) propounded various classifications at 
different times with different terminologies. At present the classification 
by Jopling W.H is adhered to : 
 
1. Type I lepra reaction   -  Reversal reaction 
    - Downgrading reaction 
2. Type II lepra reaction 
3. Type III lepra reaction 
 
Synonyms for reactional states in leprosy 
1. Leprosy reaction (Jopling W.H) 
2. Lepra reaction (Muir.E) 
3. Acute phases in leprosy (Cochrane R.G.) 
4. Acute exacerbations in leprosy (Dharmendra) 
5. Type I reaction (Bryceson) 
a) Borderline reaction 
b) Tuberculoid reaction 
c) Non lepromatous lepra reaction 
6. Reversal reaction – upgrading reaction 
7. Type II reaction 
a) ENL reaction 
b) Lepra fever (Ramu and Dharmendra) 
c) Lepromatous lepra reaction (Bryceson) 
8. Type II reaction – Lucio Phenomenon  
The plethora of terms give rise to confusion and there is a need for 
unified criteria for better understanding. The universally accepted 
terminology is that given by Jopling W.H. which can  be employed 
by all to avoid use of confusing terminologies  in the future. 
 
HISTORICAL ASPECTS 
Type I reaction : 
 In 1955 Wade H.W1 first used the term “Reversal reaction” to 
describe the appearance of skin lesions resembling those of tuberculoid 
morphology in presumed cases of lepromatous leprosy. Desouza Lima 
reported a similar reaction as “Pseudo exacerbation” and Tajiri2 as “acute 
lepromatous infiltration”. The term “upgrading reaction” was first used 
by Ridley in 1969, though Tajiri2 had earlier attempted to distinguish 
upgrading and downgrading reaction in 1955. 
Type II reaction : 
 Type II reaction was originally introduced as erythema nodosum 
leprosum. This term appeared in a paper written by Dr. M. Murata as 
early as 19123. But surprisingly for more than 50 years, ENL was not 
recognized outside Japan. 
 In 1939, Desouza Lima and Maurano4 had written that erythema 
nodosum was seen as the most frequent cutaneous symptom of lepra 
reaction, but it differed from classical erythema nodosum in which the 
lesions seldom affected the face or the nerves. 
 In 1942, Pecorano5 made a particular attempt to delineate the 
differences between erythema nodosum leprosum (ENL) and erythema 
nodosum of other etiologies and stated that ENL was considered the most 
frequent acute skin manifestation of lepra reaction and was seen usually 
in advanced cases, probably signifying improvement in prognosis. Pogge 
and Ross6 stated in an article entitled “Erythema nodosum in leprosy” 
(1946) “Leprosy is a chronic disease in which there are at least at times 
acute manifestations, the local lesions of which may be those of erythema 
nodosum or less often erysipeloid reaction of the skin, painful neuritis or 
painful lymphadenopathy”. They pointed out that erythema nodosum 
seen with leprosy was neither caused by nor cured by sulfone therapy. 
 Wolcott R.R.7 was one of the first attempt to differentiate erythema 
nodosum from other acute reactions. He pointed out that erythema 
nodosum has become much more common since the initiation of sulfone 
therapy. He pointed out that there was a correlation between anti leprosy 
treatment and the appearance of erythema nodosum as indicated by 
observation that 7% of cases occurred before treatment and 93% 
afterward. He also suggested that the presence of erythema nodosum 
indicated an increasing resistance to the disease. 
 Schujman S8 believed in a beneficial influence of lepra reaction on 
the evolution of lepromatous cases and pointed out that however frequent, 
intense and prolonged the reactions were they were beneficial to the 
patient. He said that favourable effects were greatest when they appeared 
in the early stages of the disease. He also said that “Reactions may 
sometimes cause clinical and bacteriological clearing of the lesions”. It 
was presumed that early occurring reactions are same as those that show 
bacteriological clearing and that represent the “Reversal reactions”, while 
the reactions clearing later were probably ENL cases. 
 Roche et al9 thought that the lepra reactions were essentially useful 
and that their occurrence in a patient represented a favourable sign.. 
 Contreras et al10,  stated early in 1952 that lepromatous lepra 
reaction is a grave syndrome with serious changes that might lead to 
generalized  amyloidosis and a fatal outcome.  
 Davison A.R.11, pointed out that higher the original bacteriological 
index, the more likely it was that ENL would develop. He concluded that 
ENL had a bad prognostic significance.  
 In 1959, W.H. Jopling12 introduced the terms Type I and Type II 
reactions and differentiated them.  
Type III reaction (Lucio Phenonemon) 
 This was first described by Lucio and Alvarado in Mexico in 1852. 
They described it as a necrotizing skin reaction in diffuse non nodular 
leprosy. They called this reaction “Lepra manchada”. The eponymic 
designation “Lucio’s phenomenon” was proposed by Latapi in 1948. It 
was Latapi and Zamora13 who brought the paper to the notice of the 




Type I Reaction : These occur in about 30% of patients with  
immunologically unstable borderline forms of Leprosy14. 
Type II Reaction : ENL occurs among 35% of patients in all age groups 
and 0 - 3.1% of pediatric patients with lepromatous leprosy15,16. 
INCIDENCE : 
Age: 
 Both Type I and Type II reactions occur mainly in the age group of 
20-40 years. The highest incidence of ENL reaction has been noted 
between 11-40 years, corresponding to the highest age incidence of 
leprosy in South India17. There is a high prevalence of leprosy in children. 
Majority of them tend to have indeterminate or tuberculoid type of 
leprosy18. Despite the high prevalence of leprosy in children, the 
occurrence of  both type I and type II reactions especially erythema 
nodosum leprosum  is exceedingly rare. 
Sex : 
 Both Type I and Type II reactions occur in both the sexes with 
almost equal frequency. Nerve damage is unlikely in women especially in 
reactions associated with pregnancy. The predominance of males17 in a 
study of erythema nodosum  leprosum  cases in South India19 had been 
attributed to the high proportion of male patients attending the hospital 
(10:1). Browne20 had  reported a higher incidence among males while 
Guinto21 found more females. The neuritis of type I reaction is much 
more common in patients with borderline tuberculoid leprosy. 
TYPE OF LEPROSY : 
All types of leprosy can manifest some form of reaction except the 
indeterminate type. 
Type I reaction: 
 It is typically seen in borderline spectrum of leprosy because of 
their immunological instability (i.e. BT,BB, BL). It also occurs in 10% of 
patients with subpolar lepromatous leprosy, after treatment22. Borderline 
patients may upgrade to the tuberculoid type(TT) but form a subgroup- 
secondary tuberculoid or TTs23, which in contrast to its counterpart at the 
other end of the spectrum (LLs or subpolar) appears to be 
immunologically stable24. 
Type II reaction : 
 It usually occurs in patients with multibacillary disease, who had 
enough treatment to reduce the morphological index to <5%25 and rarely 
de novo in some cases. More than 50% of patients with lepromatous 
leprosy (LLp and LLs) and 25% of patients with borderline lepromatous 
(BL) leprosy suffer from Type II reaction. 
Earlier it was believed that histoid leprosy does not go in for erythema 
nodosum leprosum. But more recently, erythema nodosum leprosum has 
been reported by some authors, 26,27,28,29 and is now occasionally observed  
in clinical practice.  
Type III reaction : (Lucio phenomenon) 
 This type of reaction is confined to the diffuse, non nodular form of 
lepromatous leprosy (Lucio leprosy), which is chiefly encountered in 
South and Central America. One case has been reported from Iran. 
Among  its unique features is the fact that it is seen only in untreated 
patients. 
 
ONSET OF REACTION WITH REFERENCE TO INITIATION OF 
TREATMENT 
 Both type I and type II reactions are seen in approximately 25% of 
the untreated patients and 50% of treated patients. 
Reversal reaction 
 More than 50% of the patients with BT and BB spectrum of 
leprosy develop reaction between 2 weeks and 6 months of starting 
therapy. About 50% of BL leprosy patients develop type I reaction, 
usually between 2weeks and 12 months after starting multi drug therapy, 
but sometimes later also if they had  downgraded to almost lepromatous 
spectrum30. Kumar et al reported that incidence of reversal reaction was 
highest during 6-12 months after starting multidrug therapy31. 
Type II reaction : 
 In about 50% of the patients, ENL reaction occurs during the 2nd & 
3rd years following treatment26. The reaction is seen when the skin lesions 
appear quiescent and all or most of the bacilli in the skin are granular24. In 
the report by Kumar et al, erythema nodosum leprosum was noted to 
occur mostly during the 2nd or 3rd year after starting MBMDT31.  
However inspite of the above facts, a patient may present with 
reaction, either type I or type II when first seen. A publication from Los 
Angeles reported a series of 32 adults presenting with reaction for the 
first time and 22 (69%) had ENL32. In a study reported from India 40% of 
patients diagnosed with lepromatous leprosy presented with ENL at the 
first visit.29
PRECIPITATING FACTORS 
 Lepra reactions are known to be precipitated by definite factors. 
They include drugs, stress, vaccinations, pregnancy etc. Wolcott (1947) 
had reported in his study that the incidence of lepra reactions rose more 
than 7% in the pre sulphone era to 93% in the post sulphone era. 
Type I reaction 
  Upgrading reaction may be precipitated by institution of 
antileprosy treatment especially dapsone, post partum state, when there is 
rapid gain of  cellular immunity lost during pregnancy, due to lepromin 
testing and when immunotherapy in the form of sensitized lymphocytes / 
lymphokines is administered.In patients with BTHD, reversal reactions 
may occur spontaneously, even before initiating treatment.  
Downgrading reaction may be precipitated by psychological stress, 
intercurrent infections, malnutrition and vaccination including BCG.25,33
It may also be precipitated by hyperthyroidism,34 oral contraceptive 
pills,35  pregnancy25, labour22 and   hormonal factors including puberty22.
Type II reaction 
The factors which are well known to precipitate Type II reaction 
include psychological stress, physical stress, surgery, physical injuries, 
menstruation, pregnancy, parturition and puberty. Ingestion of alcohol,36 
potassium iodide, Vitamin – A,33   hot foods,36    mantoux testing, 
vaccinations, extremes of heat / cold,37 intercurrent infections like 
malaria, filariasis, chicken pox, typhoid etc and drugs including 
dapsone38, longer acting sulphonamides38, thioacetazone38,rifampicin38 
etc are also postulated to play a role in precipitating Type II reactions. 
Some agents which were used as antileprosy agents in the past and 
precipitated ENL but are now more of historical interest include 
Hydnocarpus oil injection,39 diphenylthiourea and 
sulphamethopyrazine. It was previously postulated that Mycobacterium 
immunotherapy in the form of intradermal injections continued along 
with MDT can precipitate reactions. However a recent study shows no 
statistically different incidence of reactions in Mycobacterium w 
administrated group compared to a control group administrated only 
MDT40. 
CLINICAL MANIFESTATIONS : 
 Reactions are responsible for many of the symptoms that occur in 
leprosy including virtually all the symptoms of the disease that arise 
acutely. Reactions often compel the patient to seek medical attention for 
the first time. Remissions and exacerbations are the hallmark of reactions. 
The signs and symptoms of different types of reactions are as follows: 
 
Type I reaction : 
 Clinically, the most prominent sign is a rapidly developing change 
in the appearance of one or all the skin lesions - they become swollen and 
raised, erythematous, more prominent, shiny, warm to touch, often tender 
or ever painful resembling erysipelas. It can occur virtually in any site of 
the body infiltrated by a hypopigmented hypoanaesthetic patch of 
borderline leprosy. In 2004, a case has been reported by Dogra et al41 in 
which phimosis was the presenting complaint of the patient, which finally 
turned out to be a borderline lepromatous Hansen’s disease in Type I 
reaction. In another case report by Gupta et al42, of a 4 year old male child 
diagnosed with borderline lepromatous leprosy,  erythematous infiltrated 
plaques of Type I reaction have been described in the scrotal skin. 
Sometimes necrosis supervenes with breakdown and ulceration. The 
ulceration is usually superficial and heals quickly with anti-inflammatory 
therapy. The lesions desquamate as they subside and ultimately flatten 
leaving a wrinkled surface. If the lesion has been prolonged or severe, 
there may be scarring. Untreated Type I reaction tends to last for months 
or years and may relapse. The nearer the patient is to the centre of the 
spectrum, greater the number of lesions that get involved and more severe 
the changes. 
 In patients undergoing reversal reaction, new lesions are unusual, 
but when they appear, they present with well defined tuberculoid 
characteristics with discrete and thickly infiltrated margins. During the 
downgrading reaction many new lesions may appear and these will not 
tend to show the marginal definition of pre existing lesions. After each 
downgrading reaction, the lesions assume more and more borderline 
characteristics. 
 Another manifestation of type I reaction is edema of the involved 
site. It can occur over hands, feet or face either independently or together. 
Edema of the prepuce has produced phimosis41. Tenderness of the palms 
and soles are present occasionally and may sometimes herald an 
upgrading reaction. 
Neuritis is the most important component of a Type I reaction. It 
may occur together with skin changes or independently. Neuritis presents 
classically with tender enlargement of nerves at the site of prelidiction. 
Apart from the nerve being painful, the pain may be referred to the region 
of the skin which it supplies. Nerve pain causes a great deal of suffering 
and loss of sleep. There may be associated loss of function due to 
involvement or compression of the motor fibres with sudden onset of 
paralysis of the muscles of hand, foot or face resulting in wrist drop, foot 
drop or facial palsy including lagophthalmos. Anaesthesia develops 
rapidly in the region of distribution of the affected nerve. Facial palsy is 
most likely to occur when there is a lesion on the cheek. Involvement of 
the zygomatic branch is very common resulting in paralysis of orbicularis 
oculi muscle and only rarely a lower facial paralysis is seen. In facial 
nerve lesions inside the facial canal there were cases in which the chorda 
tympani along with only a single branch of facial nerve were involved 
instead of the full nerve. Sometimes the neuritis remains asymptomatic. 
Silent neuritis is seen in cases there is only slight or no tenderness on 
palpation of the nerve, but there is an increase in anaesthesia or weakness 
of muscles supplied by that nerve. Small cutaneous nerves that lie within 
a reacting patch may be completely destroyed so that a permanent patch 
of anaesthesia remains. This is uncommon on the face since there exists a 
considerable overlapping of sensory supply of different cutaneous nerves. 
Rarely, a nerve abscess forms, producing a fluctuant, tender swelling 
along the course of a nerve especially ulnar nerve, greater auricular nerve 
etc. 
 In patients co infected with HIV, who are treated with highly active 
anti retroviral therapy (HAART), Type I reaction may manifest as a form 
of immune reconstitution inflammatory syndrome43. HIV generally has 
no significant effect on the clinical course of treated and untreated 
leprosy. However it has been reported that neuritis in co-infected people 
can be more severe and the reversal reaction may be more frequent after 
therapy43. It is usually seen in the first few months of starting HAART 
(within 6 months). It usually results from an increase in cell mediated 
immunity. 
 Systemic disturbances are unusual but severe reactions may be 
accompanied by systemic illness characterized by low grade fever, 
malaise and anorexia. 
 Tenosynovitis of extensor tendons over that back of wrist may 
develop during Type I reaction. 
Grading of Type I reaction110 : 
1. Mild – Erythematous raised skin lesions with no evidence of 
neuritis. 
2. Moderate - Erythematous patches/ plaques with effusion of joints 
3. Severe – Ulceration of the skin lesions/ neuritis causing paralysis 
or impending paralysis. 
 In downgrading reaction from BL → LLs, bacillary invasion of 
previously unaffected organs especially the mucosa of the upper 
respiratory tract, eyes, phalanges and testes may occur.- 
Type II reaction : 
 Type II lepra reaction or Erythema nodosum leprosum (ENL) can 
be classified as follows, based on mode of onset of reaction45. 
1. Rheumatic type – Starts with fever, joint manifestations and skin 
lesions manifest later. 
2. Exanthematous type – Starts with fever and skin lesions 
simultaneously.  
3. Mixed type – Starts with fever, skin lesions and joint 
manifestations simultaneously. 
Grading of Type II reaction45
1. Mild – Temperature upto 100◦ F and a few skin lesions on one or 
more extremities. 
2. Moderate – Temperature upto 102◦F. Skin lesions are more 
numerous in all four limbs and few on the trunk and face with 
occasional vesicles and pustules. Extracutaneous signs present. 
3. Severe – Temperature above 102◦F. Vesiculation and pustulation 
present. Visceral involvement present. 
Cutaneous manifestations: 
 Erythema nodosum leprosum (ENL) is the most outstanding 
cutaneous manifestation of type II reaction. ENL was described by 
Green(1929) as “an acute exanthem of leprosy”. This presents most 
commonly as small 2.5mm papules or larger nodules which are warm, 
painful and tender. They may be superficial and standout clearly from the 
skin or may be placed deeply and be more palpable than visible. They are 
dome shaped with ill defined margins and erythematous to dusky brown 
in colour. They tend to appear in crops, blanch with light finger pressure 
and are evanescent lasting only 2-3 days, rarely longer. If multiple, they 
tend to be distributed bilaterally and symmetrically. Fresh crops of 
erythema nodosum leprosum tend to appear between 5.00 to 6.00PM, a 
time when endogenous cortisol production is at its lowest. ENL occurs as 
bilaterally symmetrical lesions anywhere where there has been a 
lepromatous infiltrate, although this may not have been obvious 
clinically. ENL lesions are more common on the face, arms, flexor 
aspects of forearms, and medical aspect of thighs, but the trunk is also a 
common site. In fact they may appear on any skin area excluding the 
hairy scalp, axillae groins, perineum and other intertriginous areas as 
these are warmer regions of the body avoided by M.leprae. These may 
occasionally be seen on palms and soles. ENL lesions subside with 
desquamation and leave behind a bluish stain in the skin. In case they do 
not resolve completely, a chronic painful panniculitis develops which 
may persist for months to years. Subsequently larger areas of inflamed 
skin, and subcutaneous tissue then become fixed to the underlying fascia, 
muscle or bone and may thus immobilize a hand / foot or even face. [Eg : 
Reaction of the hand with panniculitis of the dorsum of hand and arthritis 
involving interphalangeal joints]. This tissue is poorly vascularised any 
may ulcerate even with minimal trauma. The ulcer then heals slowly over 
weeks to months. 
 Apart from the classical ENL, Type II reaction can also manifest as 
vesicular, bullous, haemorrhagic (esp. around the edges of palms, soles), 
pustular (sterile pus containing polymorphonuclear leukocytes and 
degenerated AFB), ulcerated (erythema necroticum ulcerans) and 
erythema multiforme like lesions46. A few cases of bullous ENL have 
been reported from Mexico, South America, India and one case has been 
reported from Nepal47. In bullous ENL, the histopathology usually shows 
an intra epidermal cleft with diffuse polymorphonuclear infiltrate and a 
few foamy histiocytes along with a few AFB47. Erythema necroticum 
ulcerans has been reported occasionally in adults, but not in paediatric 
patients barring one case report by Pandhi et al16. Pustular and 
hemorrhagic ENL carry poor prognosis45. ENL lesions tend to recur at the 
same site. Apart from ENL, pretibial ulceration may also be seen in Type 
II reaction (due to dysproteinemia)45. 
 The relationship between leprosy and HIV infection remains 
obscure due to conflicting reports appearing over a period of time. By 
analogy with the development of active tuberculosis and other 
mycobacterial infections among HIV positive patients, an increased 
prevalence of leprosy was expected, particularly towards the lepromatous 
spectrum and possibly also the prevalence of ENL in areas where leprosy 
and HIV are endemic. Earlier literature is replete with reports of 
increased frequency of Type I reactions (reversal reactions) severe 
neuritis, poor therapeutic outcome and relapses among HIV infected 
leprosy patients48. HIV coinfection was thought to decrease the risk of 
ENL until recently when reports of  ENL among coinfected patients 
started to appear. Gebre et al49 recorded a definite higher risk of ENL 
reactions. Nand Lal Sharma et al48 also reports similar findings. HIV is 
neurotrophic and may cause necrotizing vasculitis of the nerves50. 
Possibly the interaction of neurotropicity of both M.leprae and HIV may 
result in neuropathy that is severe and unresponsive to steroid therapy51. 
Vreeburg et al52 also noted that although neuritis is equally common in 
both HIV positive and HIV negative patients, the therapeutic outcome 
with steroids was poorer in the HIV positive group.. Similarly HIV 
induced vasculopathy might aggravate immune complex mediated 
vasculitis/ panniculitis of ENL that responds poorly to steroid therapy48. 
The exact pathologic mechanism of ENL among these co infected 
patients is however, not fully understood. To summarise, increased 
incidence of ENL has been reported to occur in HIV co infected patients 
in some studies which is also poorly responsive to steroid therapy. This is 
an emerging area which needs further evaluation.  
Neuritis : 
 Type II reaction often causes neuritis. In a severe reaction, nerves 
may become painful and lose function rapidly. But more often the neuritis 
is less dramatic than in type I reaction. Affected nerves are tender and a 
little enlarged. 
Constitutional symptoms : 
 Type II reaction often produces a generalized systemic illness 
which may be severe. The fever which usually begins in the evenings, is 
usually of high grade, associated with chills and rigors. The patient may 
become exhausted and prostrated by pain, headache myalgia anorexia, 
insomnia and depression. The fever falls by lysis. Oedema of the face, 
hands & feet and painful dactylitis are other general manifestations of 
Type II reaction. 
Ocular manifestations : 
 The ocular manifestations of ENL include conjunctivitis, keratitis, 
scleritis, episcleritis, lagophthalmos, iridocyclitis and secondary 
glaucoma. Among them iridocyclitis is the most dreaded and is the most 
common cause of irreversible blindness in leprosy. It manifests as 
redness, decreased vision, pain of the whole eye which often radiates to 
the brow and the temple, photophobia, and epiphora. The eyelids are 
swollen in severe cases secondary ocular inflammation and hyperemia. 
The eye is diffusely erythematous with the most intense erythema at the 
limbus 360◦ around the cornea (ciliary flush) and severe ocular 
tenderness. There is loss of luster of the cornea due to corneal edema and 
presence of inflammatory cells and proteins in the aqueous humour (flare 
and cells). The pupil of the affected eye is usually smaller than that of the 
other eye. The above symptoms may be present in varying degrees 
depending on the severity of the reaction. Any delay in initiation of 
treatment may results in permanent loss of vision. 
 Till date, involvement of orbit in ENL has been reported only in 
one patient, where it presented as orbital apex syndrome54. While 
vasculitis due to Wegener’s granulamatosis and periarteritis nodasa have 
been implicated in orbital apex syndrome, only in the one patient, it has 
been described to be due to ENL. Involvement of the sinuses by 
lepramatous process is a well recognized entity. In the patient described 
by Dhaliwal et al54 , there was involvement of left maxillary and 
ethmoidal sinus and destruction of medical orbital wall, vasculitis of 
which probably spread to the orbit. Any inflammatory process involving 
the orbital apex (superior orbital fissure) affects III, IV, V and VI cranial 
nerves, resulting in complete ophthalmoplegia, loss of vision and 
decreased ocular sensations. Vasculitis may affect the ophthalmic, 
posterior ciliary or central retinal artery causing abrupt blindness, while 
inflammation of the connective tissue around the blood vessels can 
produce proptosis. All these conditions are ocular emergencies and that 
require urgent expert management. 
ENT manifestations : 
 Erythema nodosum leprosum can involve nasal and buccal mucosa, 
tongue and palate. It may result in nasal blockade, pain, difficulty in 
breathing, rhinitis, epistaxis, erosion, ulceration and perforation of the 
nasal septum. Involvement of the soft palate may result in ulceration and 
destruction of the uvula, deformity and scarring over the fauces. In the 
hard palate, erosion, ulceration and perforation55 can occur as a part of 
Type II reaction. In the past, involvement of larynx and consequent 
respiratory embrassment, raucous voice and aphonia have been 
described45. Cough and hoarseness of voice may also occur in ENL due to 
involvement of larynx. The gums may also be involved resulting in 
diffuse swelling of the gums. 
Musculoskeletal manifestations : 
 Myositis is a manifestation of type II reaction. The muscles 
particularly the vasti and brachioradialis may feel woody hard. Further 
more, firm, painful and tender nodules can occur in muscles rendering 
their movements painful. In the bones, periosteitis can affect tibia, 
phalanges, upper end of ulna, lower end of fibula and calcaneum. In the 
tibia, it clinically manifests as painful, soft and tender swelling, 
thickening and increased anterior curvature. Radiologically, the features 
include periosteal elevation, thickening of the cortex and increased 
anterior curvature. In the phalanges, the manifestations are pain and 
spindle shaped swelling (dactylitis). Osteoporosis is another 
manifestations of Type II reaction. It affects mainly the phalanges, 
metacarpals, long bones and ribs. Radiologically it manifests as 
pseudocysts (punched out areas of rarefaction). Resultant pathological 
fractures and subarticular collapse of bones causing shortening of digits 
may occur. “Double stripe sign” in bone scan may be seen over distal 
tibiae56. It is also seen in hypertrophic osteoarthropathy. 
 The joint manifestations of Type II reaction are arthralgia and 
arthritis with resultant non paralytic deformities. The joint manifestations 
are reportedly inversely proportional to the skin lesions45. The 
radiological findings include soft tissue swelling, osteoporosis, sub 
articular collapse, ankylosis and disorganization. 
Lymphadenitis : 
 The lymphnodes are inflamed in 50% of patients with ENL. 
Preauricular lymphadenitis is a premonitory sign of Type II reaction45. 
Other lymph nodes which may be involved include cervical, axillary, 
intercostal and inguinal nodes. Initially they are discrete and tender, but 
later become matted. In very rare instances, there may be necrosis and 
discharge through the skin53. 
Cardiovascular manifestations : 
 During Type II reaction the blood pressure is low. The blood 
vessels show leprous vasculitis and leprous meningovasculitis45. 
Pericardial friction rub has been reported.  
Respiratory system manifestation : 
 Pleuritis can be a manifestation of Type II reaction. 
Changes in testis and epididymis 
 Acute epididymo-orchitis is an important clinical manifestation of 
Type II reaction. It may be unilateral or bilateral the testes may be 
diffusely swollen and tender. Testicular atrophy may follow quickly 
either following acute orchitis or gradually following low grade orchitis. 
Gynaecomastia usually follows testicular atrophy.  
Changes in breast 
 Acute mastitis can occur in females as a result of Type II reaction.  
Changes in abdominal viscera 
 During Type II reation, the liver may be enlarged below the costal 
margin, become soft and very tender. Repeated lepra reaction can lead to 
persistent hepatomegaly, ascites, hepatic amyloidosis and splenomegaly. 
 Apart from microscopic changes observed in urine during Type II 
reaction, clinically renal involvement may manifest as glomerulonephritis 
causing frank hematuria and rarely causing oliguria. Repeated lepra 
reaction can lead to renal amyloidosis. Hypofunction of the adrenals and 
even frank peritonitis can occur during type II reaction. 
Type III reaction (Lucio phenomenon) 
 Clinically, they start as painful red patches on the skin usually on 
one side of the limbs. They are ill defined and triangular or irregular in 
shape, later becoming purpuric and the centre becomes necrotic and 
ulcerated and finally develops a black or brown crust which falls off after 
a few days to leaving a  superficial atrophic scar. Larger lesions on the 
legs are more inflamed, develop into bullae and burst leaving a deep ulcer 
with jagged edges which heals slowly if at all. 
Rea and Levan57 in their study, have found the reacting lesions to 
be most common on the legs, less commonly on the thighs, forearms and 
buttocks with sparing of trunk and face. These patients were afebrile 
throughout the course of the reaction. 
 
COMPLICATIONS 
Type I reaction 
1. Sudden onset of paralysis resulting in claw hand (ulnar and median 
nerve involvement), foot drop (lateral popliteal nerve), facial 
palsy(facial nerve) and wrist drop(radial nerve). 
2. Ulceration of the skin lesions 
Type II reaction 
1. Paralysis of  involved nerves 
2. Ulceration of the skin lesions 
3. Blindness 
4. Infertility 
5. Perforation of the nasal septum and hard palate. 
6. Secondary amyloidosis 
7. Debility and exhaustion 
Type III reaction 
1. Secondary pyoderma and cellulitis 
2. Secondary amyloidosis 
HISTOPATHOLOGY 




Type I reaction : 
 The onset of reaction is heralded by mild dermal edema. In the 
acute stages, there is profound dermal edema which causes 
disorganization and dispersal of the granuloma. In the early stages, the 
course of the reaction, whether upgrading or downgrading cannot be 
predicted. In upgrading reactions, there is increase in number of defensive 
cells such as lymphocytes, formation of giant cells and small clusters of 
epitheloid cells and decrease in number of bacilli.  
 If the reaction is of downgrading type, defensive cells are replaced 
by macrophages and there is increase in number of bacilli. 
 In severe reactions, necrosis may occur either in small foci or 
causing liquefaction of the entire granuloma and it is sometimes 
associated with local infiltration of polymorphonuclear leukocytes. There 
may be fibrinoid necrosis and finally fibrosis. As the reaction subsides, 
the granuloma takes on the characteristics of the position in the spectrum 
at which the patient was initially seen / had arrived. Biopsies of the skin 
lesion done prior to and after the subsidence of the reaction certainly aids 
in the distinguishing upgrading and downgrading reactions.  
Type II Reaction : 
 Since it is a systemic reaction, in addition to the skin, the reacting 
granulomas  may be found in nerves, lymph nodes, liver, muscle and 
synovia.  
 In the skin, the reaction is most often seen in the deep dermis or 
subcutis. 
 Histologically the reaction onset is characterized by edema of the 
papillary dermis, sharp influx of neutrophils and lymphocytes, evident as 
mixed dermal inflammatory infiltrates composed of neutrophils and 
lymphocytes superimposed on collections of foamy macrophages. The 
lymphocytes are mostly composed of CD4 cells and there is a decrease in 
numbers of CD8 T lymphocytes. Vasculitis of the nature of neutrophilic 
leukocytoclastic vasculitis affecting the arterioles or venules is a 
significant feature. Extravasated erythrocytes are often seen. Scanty 
fragmented and granular bacilli are seen around the vessels. Collections 
of small foamy histiocytic granuloma containing bacilli are seen scattered 
throughout the dermis and subcutis. The involvement of the subcutis is 
evident by mixed lobular and septal panniculitis. Direct 
immunofluoresence reveals deposition of IgG and C3 in the walls of the 
dermal blood vessels.  
 In a variant of ENL common to South East Asia, there is in 
addition to vasculitis, necrosis, involvement of the superficial dermis and 
epidermis & ulceration.  
 In another variant of ENL seen in Papua New Guinea, damage to 
collagen and elastic fibers of the dermis is the principal feature of the 
reaction, which is a variable feature of ENL elsewhere. In the late stages, 
fibrosis is intense.  
Lucio Phenomenon (Type III reaction) 
 Vascular changes are prominent features of this type of reaction 
but it differs from that seen in type II reaction. 
 There is endothelial proliferation in the medium sized vessels of 
the dermis and subcutis leading to thrombosis and associated infarction of 
the epidermis. There is a sparse largely mononuclear infiltrate with fewer 
neutrophils than in ENL. Sometimes there is prominent endothelial 
swelling and thrombosis of superficial vessels without a vasculitis. Dense 
aggregates of acid fast bacilli are found in the walls and endothelium of 
the normal appearing blood vessels as well as in the vessels with 
proliferative changes. Ischemic necrosis brought on by the vascular 
occlusion leads to hemorrhagic infarcts and results in crusted erosions or 
frank ulcers.  
IMMUNOLOGY 
 Recent advances in the field of immunology have contributed to 
better understanding of various aspects of reactional states in leprosy. 
Type I reaction  
 Type I reactions are acute inflammatory events usually occurring in 
borderline leprosy patients with immunologically unstable form of the 
disease. It is a delayed type hypersensitivity reaction (Gell and Coomb’s 
type IV hypersensitivity reaction) in which cell mediated immunity plays 
the major role. 
 Hypersensitivity can be defined as an expression of immune 
reaction in which the inflammatory response is very severe and out of 
proportion to the stimulus. The antigens released from the breaking down 
of M.leprae react with T-lymphocytes, initiating the reactional episode. 
The protein fraction of the organism tends to elicit a cell meditated 
immune response, while the polysaccharide portion elicits a humoral 
immune response.33
 During the type I reaction, the antigens are located both in the skin 
and nerves. During the reaction in the skin, hypersensitivity is directed 
mainly against surface antigens, while during the reaction in the nerves, 
hypersensitivity is directed mainly against cytoplasmic antigens 
(Bryceson). Normally during leprosy, a delicate balance exists between 
the antigens available for immune reactions and the host response. Any 
alteration of this balance induces a reactional state.  
 The cell mediated immunity always tends to localize the disease as 
seen in tuberculoid and borderline tuberculoid leprosy. In such cases, 
only few bacilli if at all are detectable in the lesions by conventional 
staining methods. In cases of acute reactional episodes, mostly only 
degraded bacilli are visualized.  
 
Reversal reaction 
 This condition is associated with a progressive increase in cell 
mediated immunity and destruction of the bacilli. Such a condition may 
occur either spontaneously or during and after completion of treatment. 
During successful treatment, the bacilli get fragmented. Each of these 
fragments act as antigens. They predict a progressive increase in cell 
mediated immunity and activation of T cells resulting in the acute 
reactional state. 
 However the reversal reaction may occur a long time after 
treatment cessation or disappearance of the lesions. (longest time reported 
is 16 years after successful treatment)58. This could possibly be because 
of persisters which had been inaccessible so far to organic defenses or 
drugs. These persisters could multiply later when conditions are 
favourable due to some intercurrent illness or immunological changes and 
initiate a new reactional episode59. Such late reversal reactions have been 
observed by investigators in the pre-sulfone era, who observed the natural 
history of some reactional cases and reported tuberculoid patients with 
reactions in which, the bacilli and the lesions resolved spontaneously 
following a reaction, only to reappear again after years of quiescence as 
erythematous lesions over previous sites with bacilli 60,61. 
 A study done by Shetty et al62, who studied 25 patients of 
borderline tuberculoid leprosy, some of whom presented with late 
reversal reactions occurring 1-13 years after release from treatment 
revealed viable bacilli in 58% of these patients (using foot pad of mouse 
culture) 
 In these cases, the cell mediated immune reaction could be related 
to the multiplication of the bacilli. The microorganisms thus destroyed 
release the antigens that give rise to a Type I reaction. If the number of 
bacilli is low, the patients become cured as the body defenses are able to 
deal with them. If the number of bacilli is high, there is a risk of new 
reactions, nerve involvement and disabilities. 
 The activation of T cells invariably occurs in cases of reversal 
reaction which is evidenced by ten fold increase of IFN – γ in these 
lesions. A four fold higher concentration of human gene serine factor 
(huHF), a marker for cytotoxic cells is also seen. Furthermore, infiltration 
of CD4 cells secreting IFN – γ and TNF – α in the skin and affected 
nerves is also seen with resultant edema and inflammation clinically63. T 
cells with γS receptors are also seen in large numbers reversal reaction64. 
γS T cells are important for granuloma formation observed in reversal 
reactions64. 
 Reversal reactions are associated with a Th1 cytokine pattern with 
IL-2 and IFN – γ strongly expressed. The expression of inflammatory 
cytokines, in particular TNF – α is thought to be responsible for 
pathological nerve damage associated with Type I reaction65. There is 
also an elevation of blood levels of these cytokines.63
It is also observed that IL – 6, IL – 10 and IL -13 are  also present in the 
granuloma of the skin lesions of patients with type I reactions66. Pro 
inflammatory cytokines have a number of effects within the granuloma. 
They include a) promotion of protective cellular responses b) 
maintainence of granuloma formation67 c) initiation of nerve damage68. In 
contrast the role of anti-inflammatory cytokines within the granuloma is 
not well understood. It can be postulated that the anti inflammatory 
cytokines play a crucial role in controlling the critical balance between 
the protective and tissue damaging effects of pro inflammatory 
cytokines66. The presence of both pro and anti inflammatory cytokines in 
these lesions highlights the multiplicity of cytokine expression within the 
granulomas of these patients and suggests that a simple model of Th1 
activation is insufficient to explain the reactional pathology. This also 
highlights the complexity of regulatory pathways within the granuloma  
 Also observed are increased levels of neopterin either at onset of 
reversal reaction or 1 month thereafter, with levels declining on 
predninolme treatment69. There is also increased conversion of 
lymphocytes to lymphoblasts and increase in Langerhans cells in the 
skin63. This immunological upgrading can be evidenced clinically by a 
previously negative lepromin test becoming positive. 
Downgrading reaction 
 This condition is associated with a reduction in cell mediated 
immunity, increase in number of bacilli and the appearance of new skin 
lesions. Such a situation occurs when the patient is not on treatment. The 
unhampered multiplication of the bacilli leads to a sudden increase in 
antigenic load, which is beyond the means of specific cell mediated 
immunity to cope up. Hence immunological downgrading results. This is 
evidenced clinically by a previously positive lepromin test becoming 
negative. 
Type II reactions 
 This is an immune complex mediated syndrome where the humoral 
immunity plays the major role. This is an example of Coomb’s and Gell 
type III hypersensitivity (Arthus phenomenon) 
 Type II reaction occurs in patients in borderline lepromatous (BL) 
and lepromatous (LL) spectrum of leprosy. It is rarely seen in histoid 
leprosy (only a few cases have been reported). In these patients, large 
amounts of mycobacterial antigens are available intracellularly in the 
macrophages and also in the intercellular spaces after release from these 
cells. A great majority of these patients also possess a high titre of 
precipitating antibodies in their serum. These antibodies lack any 
protective role. In non reactional states, they are unable to reach the 
intracellular organisms. The nature of this process which results in abrupt 
release of antigen from the macrophages is not yet fully understood, and 
it is not yet certain whether the release of antigen is an immunological 
process or otherwise. However the release of mycobacterial antigens from 
the macrophages is required for formation and deposition of immune 
complexes which induce the acute tissue damage and typical clinical 
symptoms of ENL. It has recently been observed that the antibodies in 
patients with ENL react with distinct motifs R.G.D (arginine, lysine, 
aspartic acid)38 which bind to fibronectin receptors of macrophages. 
These antibodies are mainly of IgG3 subclass63. There may be responsible 
for release of M.leprae antigens from the macrophages. 
 As already pointed out, it is the polysaccharide portion of M.leprae 
which is responsible for elicitation of the humoral immune response. 
 In ENL, the circulating antibodies contact the antigens across the 
vessel wall forming an Ag – Ab complex. The antigen antibody complex 
ratio is one of the many factors that determine the localization and 
deposition of immune complexes. ENL may be precipitated if the antigen 
– antibody ratio is balanced or if there is slight antigen excess. 
Complement is activated by the complexes and this attracts neutrophils 
whose lysosomal enzymes are responsible for much of the ensuing tissue 
damage. ENL is associated with a strong Th2 response with high 
expression of IL-4, IL-5 & IL-10. TNF – α concentration in the blood 
also rises to very high levels leading to systemic manifestations like 
fever. Further the antibodies in Type II reaction are not specific against 
M.leprae. They cross react with cardiolipin and antigen of many different 
organs. In ENL, the immune complex have been demonstrated in renal 
glomeruli and ENL lesions70,26,71. Wemambu et al71 found 
immunoglobulin and complement only in early ENL lesions and they 
reported that such deposits may not be found in specimens examined 
more than 24 hrs from their induction in laboratory animals. Circulating 
immune complexes have been described in this reaction72 and its 
symptoms have been likened to those of chronic serum sickness. It has 
also been postulated that immune complex formation in ENL may occur 
extravascularly, as evidenced by increased concentration of complement 
split product C3 in the serum of patients with active ENL25. A report by 
Patnaik et al73 attributed the exudative lesions seen in hepatic morphology 
during ENL to possible immune complex mediated mechanism. The eye 
and joint manifestations of ENL are also presumed to be due to immune 
complex mediated mechanism.  
 The immunological finding and the data supporting ENL as a 
typical immune complex mediated disease are contradicted by certain 
reports. Mshana et al74 pointed out the failure to excite arthus reaction on 
intradermal injection of M.leprae antigens into a lepromatous leprosy 
patient. It has also been noted that there is a heightened T cell reactivity 
to M.leprae antigen and increase in numbers of T cells with increase in 
CD4 / CD8 ratio upto two fold. CD8 T cells and cytotoxic T cells are 
reduced in number in skin lesions of ENL. Reversal of CD4 / CD8 ratio 
may be due to either marked increase in CD4 cells or decrease in CD8 T 
cells 74,75,76,. The decrease in CD8 T cells may induce a change in the 
amount or affinity of the anti – M.leprae antibodies which favour the 
formation and deposition of immune complexes. 
 Another phenomenon  observed in lesions of Type II reaction is a 
significant increase in apoptosis observed at 6 months of treatment77. 
Apoptosis is an active, self destructive cellular process and is considered 
an integral part of the repertoire available to the cell to respond to 
deleterious stimuli from within and without.78 Apoptosis is the end point 
of an energy dependant cascade of molecular events and is regulated by 
several genes which induce p53, c-myc, Bcl-2, CED-3 and Fas genes.78
Oliveira and colleagues found apoptosis to be greatly accelerated in 
circulating neutrophils in patients experiencing ENL.79 The increased 
expression of pro apoptotic members of Bcl – 2 family of proteins and 
TNF – α in ENL is likely to induce more apoptosis. The greater bacillary 
load and type II reaction can also lead to increase in apoptosis.77 The 
patho-mechanisms in Type II reaction may be much more complex and 
other immunological mechanisms may be involved as well. 
 The other serological abnormalities observed doing Type II 
reaction include positive tests for auto antibodies such as RA factor and 
ANA. There is an increase in circulating gamma globulins with raised 
levels of IgG, IgM, C2 & C3. The levels of c-reactive protein(CRP) also 
increases in the serum during the acute phase. 
TYPE III REACTION (LUCIO PHENOMENON) 
 The immunological features of Lucio leprosy are same as in 
lepromatous leprosy with no evidence of cell mediated immunity against 
M.leprae. Most patients have high antibody activity against M.leprae and 
its antigens. Rea suggests that these patients have singularly deficient 
defense mechanism which permits unhindered multiplication of the 
bacilli in the vascular endothelium. 
 The immunology of Lucio phenomenon is believed to be based on 
Sanarelli Schwartzman reaction80. (non allergic but hypersensitivity 
phenomenon) where the basic pathology is due to unhindered 
multiplication of M.leprae in the vascular endothelium. The exposure of 
the bacterical antigens to the circulating antibodies results in vasculitis, 
proliferation of the vascular endothelium, thrombosis, infarction and 
necrosis of the overlying skin. But the histology of the lesion also 
suggests immune complex formation and deposition within the vessel 
walls so that it can be considered as a special variant of ENL in which the 
antigen is released mainly from the infected endothelial cells. 
 If the patients with Lucio phenomenon are given a lepromin skin 
test, they usually develop and extensive local reaction (The Medina – 
Ramirez reaction), occurring within 4-6 hrs and is a reproduction of the 
lesion in Lucio phenomenon.22 Other immunological abnormalities seen 
in Lucio phenomenon are hyper gammaglobulinemia, cryoglobulinemia 
of the mixed type consisting of IgG, IgM, IgA and complement 
components and positive VDRL tests for syphilis. Direct 
immunofluoresence reveals immunoglobulin and complement component 
in the vessel walls.    
DIAGNOSIS 
 The diagnosis of reactional states in leprosy is mainly clinical. The 
following investigations could be contributory and useful for confirming 
the diagnosis under doubtful conditions. 
Type I reaction : 
 Reversal reactions and downgrading reactions may sometimes 
appear similar and pose difficulties in diagnosis. They are not associated 
with any hematological or biochemical abnormalities. Sometimes it may 
be imperative to start steroids and study the response to differentiate 
them. The following investigations may be helpful in differentiating 
them: 
Invivo tests : 
1. Lepromin test 
2. Skin biopsy 
Invitro tests : 
1. Lymphocyte transformation test 
2. Lymphocyte stimulation test 
The differences between reversal and downgrade reactions are: 
  Reversal Reaction Downgrading Reaction
1. History Pt. on treatment Pt. not on treatment / 
irregular treatment / 
defaulter  
2. Clinical findings a) No new lesions / few 
new lesions 
b) Ill defined lesions 
become well defined 
 
c) No extension in area of 
sensory deficit 
d) No new nerve 
involvement. Already 
involved nerves may be 
inflammed   
a) More no. of new 
skin lesions 
b) Well defined 
lesions become ill 
defined 
c) Extension of area 
of sensory deficit 
present 
d) New nerve 
involvement 
present  
3. Bacterial index Decreases Increases 
4. Lepromin test Negative tests revert to 
positive 
Initially positive tests 
become negative / 
weakly positive 
5. HPE Defensive cells such as 
lymphocytes, epitheloid cells 
and giant cells are increased. 
Bacilli decreased. 
Defensive cells replaced 
by macrophages. Bacilli 
increased. 
Type II reaction : 
 The diagnosis of type II reactions can be easily made on clinical grounds. 




Various hematological abnormalities can occur in type II reaction.  
a) Leukocytosis : This can be very marked ranging from 20,000 to 
50,000 cells / cu.mm and is predominantly neutrophilic.  
b) Peripheral smear : Leukemoid picture with occasional myelocytes 
and normoblasts. 
c) ESR : Usually markedly raised. 
d) Thrombocytosis : Usually present. 
e) Anemia : Normocytic normochromic anemia, megaloblastic 
anemia (due to sulpha drugs interfering with folic acid 
metabolism), aplastic anemia (due to drugs and toxins depressing 
the bone marrow) and hemolytic anemia (esp. in G-6PD def. 
individuals) can occur. 
f) In severe reactions with hemolytic crisis, sudden profound fall in 
hemoglobin values and erythrocyte count is observed. Hemolysis 
will be echoed with a rise in reticulocyte count above 2%. 
2. Biochemical 
 During the Type II reaction, abnormalities of Liver function tests 
have been reported. They include rise in SGPT and deficiency in 
coagulation factors. All these are due to moderate hepatic dysfunction 
and are reversible with the subsidence of the reaction. During severe 
reaction with hemolytic crisis, mild rise in serum bilirubin (1-2mg%) has 
been observed. Alteration of albumin to globulin ratio is another 
biochemical change reported, 73 contributed mainly by increase in α – 
globulin.  
3. Urine analysis 
 The urinary changes suggesting renal involvement in Type II 
reaction are albuminuria, (tract to 1 +), plenty of erythrocytes, pus cells 
and epithelial cells and presence of granular casts in urine. Also during 
the acute phase of type II reaction, traces of bile pigments can be found in 
urine. A patient in severe type II reaction can present with smoky urine 
due to hemoglobinuria. A persistent proteinuria following type II reaction 
should evoke the suspicion of renal amyloidosis.  
4. Skin biopsy & histopathology  
5. Fluorescent microscopy 
 Examination of early ENL lesions under fluorescent microscope 
will reveal deposits of IgG and C3 in the vessel walls. 
Type III reaction (Luciophenomenon) 
 The usual laboratory findings are leukocytosis or absolute 
neutrophilia, anemia, high ESR, hypergammaglobulinemia and positive 
cardiolipin antigen tests for syphilis22. 
 
 Histopathology and Direct immunofluorescence could confirm the 
diagnosis. 
 
DIFFERENTIAL DIAGNOSIS : 
Type I reaction :  
1. Erysipelas 
2. Urticaria   
Type II reaction 
1. Erythema nodosum leprosum 
 Other causes of erythema nodosum like tuberculosis, rheumatic 
fever and sarcoidosis should be excluded.. The features differentiating 
ENL and erythema nodosum of other causes are: 
  ENL EN 
1. Number Numerous Less numerous 
2. Site Distributed all over the 
body including face 
Less numerous usually limited to legs 
3. Nature of 
lesions 
Evanescent  No evanescence 
4 Diurnal 
variation 
Appears usually in 
evenings 
No diurnal variation 
5. Histopathology Septal panniculits with 
foamy macrophages 
containing degenerating 
AFB in the dermis. 
Septal panniculitis with dermis showing 
perivascular lymphocytic inflammatory 
infiltration in early lesions and lipid laden 
macrophages in late lesions with no AFB. 
 
2. Bullous and pustular erythema nodosum leprosum 
a) Erythema multiforme 
b) Varicella 
c) Rickettsial pox 
d) Pustular psoriasis 
e) Subcorneal pustular dermatosis 
f) Pemphigus vulgaris 
g) Bullous pemphigoid 
h) Dermatitis herpetiformis 
 
3. Conditions associated with primary panniculitis  
 Panniculitis secondary to infections, malignancy, vasculitis, 
pancreatic disease and Weber Christian disease. 
 
4. Conditions associated with connective tissue diseases 
a) Rheumatoid arthritis 
b) Systemic lupus erythematosus 
c) Scleroderma 
d) Polyarteritis nodosa 
 
5. Serum sickness 
 
Type III reaction  
1. Purpuric lesions 
a) Henoch Schoenlein purpura 
b) Pityriasis lichenoides et varioliformis acuta (PLEVA) 
c) Cutaneous allergic vasculitis 
d) Erythema elevatum diutinum 
e) Diseases with dysproteinemia 
 
2. Ulcerative skin lesions 
a) Ecthyma and other pyodermas 
b) Ischemic ulceration caused by underlying vasculitis 
c) Dysproteinemic syndromes 
d) Intravascular coagulopathy 
e) Deep mycoses 
f) Gummatous lesions 
g) Lymphoma cutis & factitia. 
 
MANAGEMENT 
 In the management of reactions in leprosy, a few general measures 
apply to all patients. 
1. Patients in mild reaction, both Type I and Type II may be treated as 
ambulatory cases and severe cases must be hospitalized for treatment. 
Bed rest to be reserved only for patients with severe reaction patterns 
and those with impending foot drop or other motor palsies.  
2. To relieve the general constitutional symptoms, an NSAID like 
aspirin (600 – 200 mg 4-6 times daily), ibuprofen (200 – 400 mg TDS), 
or indomethacin (25-50 mg BD – TDS) can be given. In patients with 
mild constitutional symptoms, paracetamol (500 mg 4-6 times daily) 
may be sufficient.  
3. To relieve the stress and anxiety, a tranquilizer / sedative may be 
prescribed. 
4. Investigations for the presence of intercurrent infections or other 
precipitating factors should be carried out. 
5. Reassurance & counseling is particularly important because the 
patient’s first assumption is that his disease is not responding to 
conventional treatment and is getting worse. Some patients may even 
discontinue antileprosy drugs or may go for native medicines. They can 
be assured that they are recovering their lost immunity and the disease 
is getting eliminated. 
6. Anti leprosy therapy : Though much controversy had prevailed in 
the past about the continuation of antileprosy therapy (esp. dapsone) 
during reaction, the present view is that it should be continued in full 
dose during the reactions also with following hints of caution: 
a)  In patients who present for the first time with severe neuritis, 
dapsone may be replaced by clofazamine and thiambutosine, along with 
NSAIDs and steroids.  
b) Some patients with borderline leprosy go in for severe reactions 
within a few weeks after initiating MBMDT. Previously when dapsone 
monotherapy was practiced, it was replaced by clofazamine. Nowadays 
with the advent of MBMDT, it is no longer imperative to withdraw 
dapsone. However in case of severe uncontrollable and steroid 
dependant reactions, dapsone may be withdrawn temporarily, which 
may allow steroids to be withdrawn later. 
 
ANTIREACTION DRUGS   
1. Corticosteroids  
 Corticosteroids form the mainstay of management of both Type I 
and Type II reactions in leprosy. In managing reactions, early 
intervention is crucial if permanent nerve damage is to be avoided and 
impairment of function is to be reversed. Corticosteroids are the only 
drugs known which can quickly reverse the inflammation and help in 
restoring function. 
 In 1950, Chaussinand in his textbook ‘La Lepre’ first mentioned 
about the use of cortisol / ACTH in the treatment of Type I reaction. 
Thereafter it was incorporated and brought into general use for the 
treatment of Type I & Type II reactions. It action in Type I and Type II 
reactions is by virtue of its anti-inflammatory and immunosuppressive 
properties.      
Hence steroids cause inhibition of both early and late phases of 
inflammation. The preferential depletion of CD4 T cells and B helper 
cells (those with Fc receptors for IgM) result in normalization of 
disturbed helper suppressor T cell ratio as seen in erythema nodosum 
leprosum. These compounds also have been found to prevent and control 
adjuvant arthritis possibly due to redistribution of T cells. 
Dose : T.Prednisolone 40 – 80 mg / daily, which is gradually 
tapered.  
It can however cause adverse effects like exacerbation of acid 
peptic disease, growth impairment in children, HPA axis suppression, 
hypertension, hyperglycemia, reactivation of latent infections, etc and its 
use is to be governed by strict supervision. 
2. Thalidomide  
 Thalidomide or α – (N phalimido) glutarimide was first developed 
in 1954  and marketed in 1957 for use as sedative / antiemetic in pregnant 
women. In the early 1960s its teratogenic potential was identified and the 
drug went out of market in 1961. In 1965, Sheskin reported the 
effectiveness of thalidomide in the management of ENL82. 
 Thalidomide is a racemic glutamic acid analogue composed of two 
enantoimers R – and S-  Thalidomide, which interconvert under 
physiologic conditions. The two enantiomers have differing properties; 
one is a more potent suppressor of TNF release by stimulated blood 
mononuclear cells while the other is sedative83. Thalidomide undergoes 
hydrolysis at pH 7.0 resulting in the formation of more than 20 products, 
which are responsible for the activity. It is effective only in Type II 
reaction. 
 It is anti-inflammatory in nature and acts by inhibiting the release 
of TNF, IFN – α, IL-10, 12, cyclo-oxygenase and NF-kB. It also 
decreases the effect of complement derived chemotactic factors resulting 
in reduced or non recruitment of polymorphonuclear leukocytes into the 
lesions. It is also said to result in improvement of motor conduction 
velocities of nerves involved in erythema nodosum leprosum. 
 
Dose : Initial  :  100 – 300 mg / day in divided doses 
  Maintenance  :  50 mg / day 
It results in teratogenicity (phocomelia) if the drug is taken 
between 35th – 50th day post LMP. It also causes drowsiness, sedation and 
irreversible peripheral neuropathy.  
 
 
3. Clofazamine (Lamprene)  
 This red immunophenazine dye was first discovered by Dr. 
Vincent Barry in his laboratory in Dublin and it was Dr. Stanley Browne 
who first used it clinically in leprosy. It is a part of the multibacillary 
drug regimen for leprosy. 
 It is useful in patients with Type II reaction and those with severe 
Type I reaction, who have become steroid dependant85. It decreases 
neutrophil chemotaxis with consequent decreased influx of polymorphs 
into the inflamed area85. It decreases antibody formation, with consequent 
control and prevention of reactions85. It also increases synthesis of 
lysosomal enzymes and enhances phagocytic ability of macrophages, 
resulting in complete digestion of antigens or degradation of antigens to 
less antigenic forms85. 
The drug is, however very slow to act taking weeks for its full 
effect indicating the need to add other drugs for the management of 
acute / subacute manifestations. The drug has only a limited role in 
neuritis since it takes too long for any significant effect. The 
usefulness of this drug lies in its being primarily an anti-leprosy drug 
being helpful in management of chronic recurrent erythema nodosum 
leprosum as also in with drawing steroids in steroid dependant cases. 
Dose : Initial  : 300 – 400 mg / day 
   Maintenance  :  100 mg/ day 
1. It can cause certain undesirable adverse effects including reddish 
brown pigmentation of the skin, conjunctiva, body secretions & 
feces, brownish corneal deposits and retinal spots, ichthyosis and  
pruritus. It can also cause photosensitivity and eosinophilic 
enteritis. 
 
4. Chloroquine   
 It is a 4 aminoquinoline derivative used as an antimalarial drug. It 
is used primarily in reactions in leprosy due to its antiinflammatory 
nature. It is useful in mild Type I reaction, where ulceration and neuritis 
do not occur and for mild to moderate ENL without complications.  
Dose: Initially chloroquine is given in a dose of 250mg thrice daily for 
the 1st week, 250mg twice daily for the 2nd week and 250mg  once daily 
thereafter. 250 mg OD on alternate days is sufficient to maintain control.   
 It can cause gastrointestinal upset, hemolytic anemia, blurred 
vision, hypertension, cardiovascular collapse, lichenoid dermatitis, flare 
up of psoriasis and bleaching of hair and moustache.  
 
5. Antimonials :  
 With the advent of conticosteroids, thalidomide and clofazamine in 
the treatment of lepra reactions, antimonials are less frequently used 
because they are less effective and more toxic. Potassium antimony 
tartrate and stibophen are examples of this group of drugs. The former 
can be used only intravenously and the latter is given intramuscularly. No 
oral preparations are available. They are particularly useful in relieving 
the pain in bones & joints in Type II reaction and for mild type I reaction, 
where neuritis and ulceration do not occur. 
Dose: Potassium antimony tartrate : The usual dose is given as 0.5 – 1% 
solution I.V. This is repeated every other day. The dose may slowly be 
raised from 20 to 60 mg based on the clinical response. The total dose 
should not exceed 500-1000 mg. If no response is seen by 6th dose, it is 
unlikely to be effective and the drug is withdrawn.  
Stibophen: The initial dose is 1.5 ml i.m and if no adverse reaction 
occurs, 3.0 ml is given 2 days later followed by 3-5 ml on alternate days. 
The total dose should not exceed 30 ml and if no response is seen by 6th 
dose, it is withdrawn. 
 The courses of both potassium antimony tartrate and stibophen 
may be repeated if necessary after an interval of several weeks. 
However, there is a risk of severe anaphylactoid reactions, pneumonia, 
joint & muscle pain, acute arthritis, hepatitis, renal damage and cardiac 
toxicity.  
6. Colchicine  
 It has been found to be useful in Type II reactions, particularly in 
frequent or recurrent severe ENL reactions. In a dose of 1.5 – 2 mg daily 
in divided doses86, it is reported to have dramatic effects in controlling 
fever and erythema nodosum leprosum. It is also indicated in the 
treatment of amyloidosis secondary to chronic skin ulceration22 and has 
prophylactic value in patients without amyloidosis. It probably owes its 
effectiveness to its ability to inhibit neutrophil chemotaxis. This drug also 
restores T cell balance85. 
7. Zinc 
 This drug is under extensive trial. It is recommended in treatment 
of erythema nodosum leprosum and chronic leg ulceration resulting from 
necrotic ENL lesions. It is reported to have inhibiting effect on neutrophic 
chemotaxis and complement mediated reactions. In a study by Mathur et 
al87, out of 8 patients with ENL treated using oral zinc sulphate, steroids 
could be withdrawn completely in 7 patients with reduction in weekly 
dose of clofazamine and better tolerance of dapsone. The recommended 
dose is 220 mg TDS. 
 
8. Azathioprine   
 It has been reported to be effective in the management of severe or 
refractory Type II reaction88,89. The recommended dosage is 50 mg/day. It 
reduces sythesis of TNF – α, thus serving as a potent anti-inflammatory 
agent. It also appears to be safe during pregnancy90. 
 
9. Methotrexate  
 Methotrexate also is useful in treatment of severe and refractory 
ENL91. But it is highly teratogenic and both men and women are advised 
to avoid planning pregnancy while on methotrexate and for 6 months 
after stopping it.  
10. Mycophenolate Mofetil 
 It has been reported to be useful in treatment of erythema nodosum 
leprosum. Mycophenolate mofetil is the prodrug of mycophenolic acid, 
which is a potent inhibitor of type II isoform of inosine monophosphate 
dehydrogenase, which is expressed in activated T & B lymphocytes. Its 
efficacy is mainly due to induction of apoptosis of activated T cells92, 
eliminating clones of cells responding to antigenic stimulating92. 
Depleting guanosine nucleotides, it also suppresses glycosylation and 
expression of some adhesion molecules. It also depletes 
tetrahydrobioterin, which is a cofactor for inducible form of nitric oxide 
synthetase – iNos92. It is used in a dosage of 0.5gm twice a day with dose 
reduction over 4-6 months and further followed for another 2 months92. It 
is useful as a steroid sparing agent and in patients in whom systemic 
steroids are contraindicated.  
11. Pentoxyphylline 
 It is a methylxanthine derivative with potent haemorrheologic 
properties used for intermittent claudication and chronic leg ulcers. It also 
has immunomodulating effect due to suppression of monocyte production 
of TNF – α and IL-193. It is hence useful in Type II reactions in leprosy. It 
is useful to some extent in a dose of 1.2gm daily91. 
12. Cyclosporine – A  
 The role of cyclosporine in ENL was thought to be promising 
following invitro studies, but however relevant clinical data are lacking91.  
It was first tested invitro using peripheral blood mononuclear cells from 
ENL patients. It was found that lepromin induced Con-A suppression of 
suppressor cells was reversed with predominant effect on adherent cells85. 
It was found useful in a small series of 3 patients, when given in a dose of 
100-200 mg daily85. The limiting factors were GIT symptoms observed in 
all three patients.  
13. Levamisole  
 Some reports are available in literature which state levamisole has 
been useful in ENL cases. However the results have not been 
encouraging. The possible consideration for its use was its ability to 
restore T cell numbers to normal85. 
14. Aspirin and Indomethacin  
 Aspirin has been evaluated in the treatment of ENL in three double 
blind controlled trials and indomethacin in one. Both were found less 
effective than thalidomide and prednisolone. In one study, aspirin was 
compared with colchicine in the management of ENL and both were 
equally effective in mild disease94. 
15. Trepterygium Wilferdin hook – A Chinese Herb  
 This herb has been reported to be effective in both Type I and Type 
II reactions, with efficacy of 96.6% and 98% respectively85. This herb is 
also effective in suppressing neuralgia. 
16. Plasmapheresis  
 This method has been employed in treatment of both type I and 
type II reactions85 and involves replacement of plasma of the patient with 
sterile albumin solution. It has been suggested that type I reaction is on 
account of appearance of some plasma factors that augment LTT 
response of lymphocytes. The removal of this immunostimulatory factors 
results in beneficial effect by reducing the hypersensitivity response85. It 
also has been seen to be effective in ENL. Its possible mechanism 
includes dilution of cytokines, free antigens and antibodies85. 
17. Zafirlukast  
 This leukotriene antagonist has been tried in an open phase II 
cohort trial using an initial dose of 40 mg twice daily. It was effective in 





 The successful use of this chimeric monoclonal antibody, which 
suppresses the biological activity of TNF by specifically binding to it has 
been reported in a single case of recurrent ENL treated in Netherlands96. 
 
MANAGEMENT OF Type I REACTION  
 The 7th WHO expert committee on leprosy stated in June 199797 
that the crucial elements in the management of leprosy reactions and 
thereby the prevention of disabilities are early diagnosis of reactions 
together with prompt and adequate treatment. Corticosteroids are the 
sheet anchor of treating reversal reactions. Mild reactions without neuritis 
can be adequately managed using aspirin and chloroquine. WHO states 
that for severe reactions and neuritis less than 6 months, the 
recommended dose of prednisolone is 40-60 mg daily, gradually reduced 
and tapered weekly or fortnightly and stopping after 12 weeks98. All 
patients with recent nerve function impairment < 6 months duration 
demonstrate greater improvement in nerve function than those with old 
impairments98. 
 WHO regimen is clearly very short in which the  prednisolone dose 
stayed above the crucial dose of 15-20mg only during the first 2-3 
months. Some authors however have stated that such a short treatment 
could not be effective in the long run81. Researchers at All Africa Leprosy 
and Rehabilitation Training Centre (ALERT) have used a regimen 
consisting of T.prednisolone 30-40 mg once daily, which after 1 month 
was reduced over a 2-3 months period to 20—25 mg. Thereafter 
prednisolone was decreased by 5 mg once a month. The dose was 
increased again to the previous dose when nerve function parameter 
deteriorated. It was noted that 15-20 mg was the critical dose of 
prednisolone required to control a reversal reaction after the initial period. 
The total treatment duration was 4-9 months for BT patients, 4-14 months 
for BB patients and 6-20 months for BL patients. A study by Li Huan 
Ying99 reporting on the duration of reversal reaction, states that only 
39.6% of reactions subsided in less than 3 months and 62.1% within 6 
months. In 22.2% of BL patients it was found that reversal reaction lasted 
at least 7-12 months. Other evidence supporting prolonged treatment with 
prednisolone was recently reported by Little et al100, who observed that 
there was a continuing Th1 cytokine activity even 180 days after start of 
prednisolone in some of the patients at follow up. At the 16th International 
Leprosy Congress in Salvador, Bahia, Brazil, P.S.Rao presented a 
controlled trial of different prednisolone dosages and durations in type I 
reactions based on a protocol written by Lienhardt, which showed clearly 
that the longer duration was statistically better than the shorter duration, 
but the initial dose (60 mg compared to 30 mg) was not significant81. A 
treatment proposal by Ben Naafs81 is as follows with T. prednisolone 
once daily in the morning.  
 
Paucibacilary   Multibacilllary  
40 mg 2 wks    30 mg 1 month 
30 mg 2 wks   25 mg 2 months 
25 mg 1 month   20 mg 3 months 
20 mg 2 months   15 mg 2 months 
15 mg 1 months   10 mg 2 weeks 
10 mg 2 weeks   5 mg 2 weeks 
5 mg 2 weeks   
Total – 6 months   Total – 9 months 
 
 The use of high dose corticosteroids is not without adverse effects, 
which are very common. Hence patient monitoring is considered very 
important. The following parameters are taken into account:  
a) Monitor blood pressure and weight at each visit 
b) Urine analysis & blood glucose estimation 
c) Gastric protection with H2 blocker or proton pump inhibitor.  
d) Treat those at rise of strongyloides stercoralis with albendazole / 
ivermectin 
e) Osteoporosis prevention. 
Immunosuppresants like azathioprine are also said to be effective in 
type I reactions. Azathioprine in combination with an 8 week course of 
prednisolone was as effective as a 12 week course of prednisolone alone 
in the management of type I reactions in a pilot study done in Nepal101. 
Antileprosy drugs  
 If the patient is on treatment with dapsone at the time of reaction, it 
is generally continued at its full dose. In case the patient is not on 
dapsone at the onset of reaction it can be started after the reaction is 
brought under control. In ALERT dapsone was discontinued for the first 
2 weeks of antireaction treatment thereafter restarted and continued at its 
full dose.  
Neuritis  
The various modalities of management of neuritis are: 
a) NSAIDs 
b) Anti reaction drugs esp. corticosteroids which cause dispersion of 
intraneuronal edema.  
c) Suitable supportive therapy for paralysed muscles in the form of 
padded splints. Sessions of graduated passive and active exercise 
will aid muscle recovery and prevent stiffness of joints. 
d) Intraneural injections – This can be given for relief of severe nerve 
pain. A combination of 1500 units of hyaluronidase, 1 ml of 2% 
lignocaine and 1 ml of hydrocortisone suspension containing 25 
mg/ml is injected into the swollen nerve or around it using 14 size 
needle after infillrating the skin with local anaesthetic agent.  
e) Surgical treatment : - Surgery also finds a role in the management 
of neuritis, esp that of ulnar neuritis, but also of other nerves as 
well. The various surgical procedures include nerve decompression 
(neurolysis), decompression with transposition and decompression 
with epicondilectomy. The indications for nerve decompression 
are:  
a) Severe intractable pain 
b) Nerve abscess 
c) Recurrent neuritis 
d) Increased weakness of muscles and impending paralysis 
e) Cases not responding to medical management within 4 
weeks102. 
Downgrading reaction  
 This is usually managed by continuation of appropriate antileprotic 
therapy. For patients with neuritis or marked erythema or edema of skin 
lesions, a brief course of corticosteroids may be beneficial. 
 
MANAGEMENT OF Type II REACTION  
 There are three patterns of erythema nodosum leprosum, which 
was identified in a cohort of 82 Indian patients. They are acute single 
episodes, recurrent acute episodes and chronic ENL91. Acute single 
episodes were defined as a single episode responding to steroid treatment 
and accounted for only 6% of the episodes. Recurrent acute episodes 
comprised recurrent episodes with periods off all treatment. It comprised 
32% of all case types. It was termed chronic when patients needed steroid 
treatment for more than 6 months. It accounted for 62% of all case 
types91. In 1998, WHO expert committee on leprosy report discussed the 
management of Type I (reversal) reactions and ENL together103 advising 
that severe ENL can be treated with prednisolone, as for reversal reaction 
(a 12 week course), with the maximum dose not exceeding 1mg/ kg body 
weight. The ILEP technical bulletin on the management of ENL 
recommends treating severe ENL with corticosteroids at a starting dose of 
30-60mg and reducing every week by 5-10mg. It states that a 
maintenance dose of 5-10mg may be needed for several weeks to prevent 
recurrence of ENL104. When clofazamine is used at a dose of 300mg, 
WHO expert committee recommends that the drug should not maintained 
at this dose for more than one year.103 On use of thalidomide, WHO 
expert committee advises that it should be given only to men or post 
menopausal women who are dependant as corticosteroids.103 ENL can be 
managed as given below: 
Mild reactions  
a) Aspirin (or) paracetamol 
b) Sedatives 
c) Chloroquine 250mg TDS x 2 weeks 
Moderate reaction  
a) Sedatives 
b) Aspirin 300mg TDS or as necessary 
c) Chloroquine 250mg TDS (till fever subsides)  
d) Prednisolone 20-40mg daily, tapered off in 4-6 weeks. 
e) Previously, Sodium antimony gluconate was given : 20mg in 
alternate days x 3 – 6 doses. 
Severe reaction  
a) Rest, analysis, sedatives 
b) Prednisolone 40-60mg / day, tapered off in 4-6 weeks 
c) Previously,thalidomide was given. 
d) Clofazamine 100mg TDS initially, then tapered to 50mg daily 
e) In case of severe recurrent erythema nodosum leprosum, pulsed 
intravenous corticosteroids have been tried once monthly along 
with azathioprine in a dose of 50mg daily by Mahajan et al105. 
f) Management of complications. 
In case of severe recurrent chronic erythema nodosum leprosum pulsed 
intravenous corticosteroids along with azathioprine 50 mg daily can be 
tried as suggested by Mahajan et al104
 
Type III rection (Luciophenonenon) 
Mild cases  : Self limiting 
Moderate to severe cases : Steroids are moderately effective. To 
start with atleast 60mg prednisolone should be given daily which can be 
tapered off over several weeks. Thalidomide and clofazamine are 
ineffective. All therapy including immunosuppressants are ineffective. 
Plasmapheresis is reported to be effective.  
 
AIMS AND OBJECTIVES  
1. To find out the age and sex incidence of different types of 
reactional states in leprosy. 
2. To study the incidence of different types of reactions occurring 
across the spectrum of leprosy. 
3. To study the onset of reaction  in relation to duration of disease and 
initiation of treatment and the frequency of exacerbations.. 
4. To study the different signs and symptoms associated with Type I 
and Type II lepra reactions. 
5. To study the clinical and histopatholoical correlation of Type I and 
Type II lepra reactions. 
 
MATERIALS AND METHODS 
 Fifty patients presenting to the leprosy out patient department with 
any type of lepra reaction between August 2008 and July 2009 were 
included for the study. This included both old and new cases. As per 
WHO recommendation, patients with multibacillary disease are treated 
for 12 months and those with paucibacillary disease are treated for 6 
months. All patients presenting with reaction, including  those who are 
already on antileprosy drugs and new patients seeking medical attention 
for the first time were  included in the study. A detailed case proforma 
was prepared for each patient which included the patients’ demographic 
details, detailed history, time of starting MDT, regimen followed and 
time of stopping MDT. The clinical features were noted and the clinical 
type of leprosy and the type of leprosy reaction was assessed. The time of 
developing leprosy reaction, recurrence of reaction within 6 months, 
neurological symptoms  and signs including nerve tenderness, pain, new 
disability were all noted down carefully. Initial bacteriological index was 
estimated and a biopsy and histopathological study was done for all the 
patients. Other investigations including complete blood count, renal 
function test, liver function test, serum electrolytes, X-ray chest and 
smear for MP/MF was also done. 
Definition of Leprosy reaction  
 Type I reaction was diagnosed  if existing skin lesions became 
inflammed or if the patients developed nerve tenderness and new nerve 
functional impairment (sensory or motor). Type II reaction was diagnosed 
if the patient developed crops of erythematous tender nodules (erythema 
nodosum leprosum) with the presence of any of the following : fever, 
malaise, peripheral nerve pain or tenderness, joint pain, lymphadenitis, 
iridocyclitis or orchitis. If the patients had nerve pain, nerve thicknening 
or nerve tenderness, they were diagnosed as neuritis. Grading of both 
Type I and  Type II reactions was also done.  
Treatment and followup  
 Type I reaction, including neuritis was treated using analgesics, 
chloroquine, antibiotics and a standard 12 week course of steroids as 
recommended by WHO with a starting dose of  40mg / day. Type II 
reaction was also treated  using the same dose of T.prednisolone 40mg / 
day tapered gradually once in two weeks. Clofazamine was used in two 
patients and pentoxyphylline in one patient who had repeated 
exacerbations and could not be weaned from steroids. All the patients 
were followed up for a minimum period of 6 months.  
 
RESULTS  
A total of fifty patients were included in the study. There were 30 patients 
with Type I reaction and 20 patients with Type II reaction. There were no 
patients with Type III reaction.  
 The mean ages of patients with Type I and Type II reactions were 
39.83 yrs and 37.45 yrs respectively. 25 (50%) of the patients  in either 
reaction were found in the age group of 21- 40 years. 13 (26%) were aged 
above 50 years, 8 (16%) were between 41 – 50 years and only 4 (8%) 
were less than 20 yrs old, the youngest patient being a boy 15 years of 
age. (Table  1, Figure  1) 
  There were a total of 34 male patients and 16 female patients, with a sex 
ratio of 2.12. The  sex ratios of patients with Type I and Type II reactions 
were 1.3 and 4.0 respectively. Thus male patients constituted 68% of the 
total number of cases.   
Out of the 30 patients with Type I reaction, 28 were upgrading and two 
were downgrading (Figure 3). It was also noted that out of 28 patients in 
Type I upgrading reaction, 26 (92.85%) were primarily diagnosed as 
borderline tuberculoid Hansen’s disease and the remaining 2 (7.15%) as 
borderline lepromatous Hansen’s disease. Among the 2 patients with 
downgrading reaction, 1 was diagnosed with borderline tuberculoid  


 Onset of reaction in relation to 





Started with reaction 12 (40%) 2 (10%) 
< 6 months 3 (10%) 4 (20%) 
6 months – 1 year 3 (10%) 0 
1-3 years 7 (23.33%) 6 (30%) 
3-5 years 4 (13.33%) 6 (30%) 
> 5 years 1 (3.33%)  2(10%) 

d 
owngrading to mid  borderline and the other patient with mid borderline 
downgrading to borderline lepromatous leprosy.  Among the 20 patients 
who developed type II reaction, 13 (65%) of them were primarily 
diagnosed with lepromatous leprosy. Four patients (20%) belonged to the 
borderline lepromatous spectrum and the remaining 3 (15%) were 
diagnosed to have histoid leprosy.(Table  2, Figure 2) 
 It was observed that among the 30 patients with Type I reaction, 12 
(40%) presented with reaction before initiation of MBMDT 
(Multibacillary Multidrug therapy). Three patients (10%) developed Type 
I reaction within 6 months of starting MBMDT and 3 (10%) developed 
the reaction after 6 months. Seven patients (23.33%) developed Type I 
reaction between 1-3 years after initiation of therapy and 4 (13.33%) 
developed the reaction between 3-5 years after starting therapy. Only 1 
patient (3.33%) developed the reaction after 5 years of therapy. Among 
patients with Type II reaction, 2 (10%) presented with reaction before 
diagnosis and initiation of MBMDT  and 4 (20%) developed the reaction 
within 6 months of initiation of therapy. Six patients (30%)  each 
presented with reaction between 1-3 years and 3 -5 years after initiation 
of therapy. Only 2 patients (10%) developed Type II reaction 5 years 
after initiation of therapy. (Table 3, Figure 4) 
  

 Apart from the raised erythematous skin lesions which were found in all 
the patients, neuritis was the predominant feature in Type I reaction. It 
was seen in 14 (46.6%) patients. Ulnar nerve and lateral popliteal nerve 
were seen to be predominantly involved. During the time of reaction, 
deformities like claw hand, foot drop and facial palsy was seen in 4 
(13.3%), 2 (6.6%) and 1 (3.3%) patients respectively. Fever was seen 
only in 5 (17%) patients. Oedema of the extremities were seen in 10 
(33.3%) of the patients. In patients with type II reaction, fever was noted 
in all the patients, arthralgia in 14 (70%), oedema of the extremities in 17 
(85%), oedema of the face in 7 (35%), neuritis in 8 (40%), iritis in 1 
(5%), orchitis in 2 (10%) and lymphadenitis in 8 (40%) patients (Table 4, 
Figure 5). Among patients with Type I reaction, 16 (53.33%) had mild 
form of reaction, 5 (16.66%) had moderate form and 9 (30%) had severe 
reaction. Among patients with Type II reaction, 2 (10%) had mild form, 
11 (55%) had moderate form and 7 (35%) had severe form of reaction. 
(Table 5,Figure 6) 
 During the follow up, exacerbation of Type I reaction was seen in 13 
(43%) patients. Among these 13 patients, 10 (76.93%) of them had 
exacerbations after 12 weeks of WHO recommended regimen. The rest of 
them (23.07%) had exacerbations within the 12 week period when the 








Epidermal changes  12 (40%) 15 (75%) 
Grenz zone - 16 (80%) 
Dermal edema 22 (73.33%) 16 (80%) 
Epitheloid granuloma 30 (100%) - 
Infiltrate in dermis - 10 (50%) 
Infiltrate in dermis + 
subcutis 
- 10 (50%) 
Neutrophilic abscess - 10 (50%) 
Vasculitis - 10 (50%) 
Panniculitis - 10 (50%) 
Fragmented AFB +ve  - 16 (80%) 
severe reaction and 4 (30.76%) had moderate reaction. 7 out of 13 
patients (54%) had repeated episodes of flare ups and required steroids 
for more than 6 months. Among the patients with Type II reaction, 15 
(75%) had exacerbation of reaction. Among these 15 patients, 10 
(66.66%) of them had exacerbations in the standard 12 week period even 
before tapering could be completed when the dose of steroids was being 
brought down to <20 mg. The remaining 5 patients (33.33%) had 
exacerbations after the standard 12 week period when the steroids were 
continued in a low dose (<=10 mg) or stopped.  Among these 15 patients, 
7 (46.66%) had severe reaction and 7 (46.66%) had moderate reaction. 
Twelve (80%) of the patients who exacerbated  had repeated flare ups and 
required steroids for more than 6 months (Table 6, Figure 7). Only one 
patient with Type II reaction could not be followed till the end of the 
study due to his sudden demise in a road traffic accident.    
Twenty seven (90%) patients in Type I reaction were negative for AFB in 
slit skin smears and the other 3 (10%) had a bacteriological index (BI) of 
1+. Nine patients (45%)  with ENL had a BI of >=4, 5 (25%) had a BI 
between 2-3, 1 (5%) had a BI of 1+ and 5 (25%) had negative smears. 
(Table 7, Figure 8)  
Study of the histopathological sections of patients with Type I upgrading 





























































































































reaction. An increase in the number of lymphocytes and multinucleate 
giant cells was also observed. Foci of fibrinoid necrosis and destruction 
of the appendages were seen in 21 (75%) patients. Edema in the dermis 
with hazy collagen fibers were seen in 21 (75%) of them. Epidermal 
changes were seen in 8 (40%) of the patients, with 5 of them having an 
epitheloid granuloma eroding into the epidermis. All these features 
correlated with the degree of severity of the clinical presentation. In 
patients with downgrading reaction, epitheloid granuloma admixed with 
lymphocytes and macrophages with acid fast bacilli were seen. In patients 
with Type II reaction, neutrophilic infiltration of the dermis overlying a 
focus of foamy macrophages was seen in all the patients. Dermal edema 
and Grenz zone were observed in 16 (80%) patients. Ten patients (50%) 
had neutrophilic abscess, panniculitis & vasculitis.  Fragmented acid fast 
bacilli were seen in 16 patients (80%).(Table 8, Figure 9,10). Erythrocyte 
sedimentation rate (ESR) was found to be raised in all patients with Type 
II reaction. All other laboratory parameters were found to be within 
normal limits. 
DISCUSSION 
 Several interesting observations have been made in our study. In 
our study, 50% of the patients were in the 21-40 year age group. The 
highest age incidence of  both Type I and Type II lepra reactions have 
been  noted  between 21-40 years (Hemerijckx F).17 Male patients 
constituted 68% of the total which clearly correlates with the findings of 
the previous studies done at Belgian leprosy centre, Polambakkam, 
Madurantakam, South India17and Job et al19. 
92.85% of the patients in Type I reaction belonged to the 
borderline tuberculoid spectrum and 65% of the patients with Type II 
reaction belonged to the lepromatous spectrum in our study, which is also 
consistent with the findings of Kumar et al31 and Vijayakumaran106. 
 Among the patients with Type I reactions 40% developed the 
reaction before initiation of MDT. 10% developed Type I reaction within 
6 months of starting MBMDT and 10% developed the reaction after 6 
months. 23.33% of patients developed Type I reaction between 1-3 years 
after initiation of therapy and 13.33% developed the reaction between 3-5 
years after starting therapy. 3.33% developed the reaction after 5 years of 
therapy. Kumar et al31 reported that the incidence of reversal reaction was 
highest during 6-12 months after starting MDT. Vijayakumaran106 et al 
had reported that most patients developed a reaction during the first 3 
years of surveillance. This is different from that found in our study as 
40% of our patients had developed Type I reaction de novo. Among the 
patients who developed Type II reaction, 30% each developed the 
reaction between 1-3 years and 3 -5 years after initiation of therapy 
respectively. Kumar et al31   reported that ENL occurred mostly during 2nd 
or 3rd year following MDT. This has correlated well with the findings in 
our study. In histoid leprosy, ENL reaction has been reported by some 
authors, 26,27,28,29. . We had three patients with histoid leprosy who 
developed erythema nodosum leprosum (ENL). One of them developed 
ENL during the first year of treatment with MBMDT (multibacillary 
multidrug therapy) and two of them developed the reaction post 
MBMDT.  
 Apart from raised erythematous skin lesions, which were seen in 
all patients, neuritis was the predominant feature in Type I reaction, and 
was seen in 47% of the patients. Deformities like claw hand, foot drop 
and facial palsy was seen in 13%, 7% and 3% of the patients respectively 
in our study. Sharma107 reported that 7.9% of patients developed claw 
hand during and after MDT. Richardus108 also reported that 7.9% of 
previously normal MB patients developed nerve function impairment due 
to reaction. In our study, claw hand was seen in 13% and nerve function 
impairment in 20% (one patient had both claw hand and foot drop) which 
is only slightly higher than that seen by Sharma107 and Richardus.108    In 
patients with type II reaction, fever was noted in all the cases, arthralgia 
in 70%, edema of extremities in 85% and neuritis in 40% of the cases. All 
these findings of our study correlate well with those of Kumar et al31. 
 Exacerbation of Type I reaction was seen in 43% of the cases with 
most of them (77%) developing it after 12 weeks of steroid therapy. All 
those patients who had severe reaction required steroids for more than 6 
months. In case of Type II reaction, exacerbations were observed in 75% 
of the patients with 50% of them observing exacerbations within 12 
weeks of steroid therapy when the dose was being tapered to <20 mg. All 
those patients who had severe reaction required steroids for more than 6 
months.  Shen et al109 found that the standard 12 week regime of 
prednisolone was effective only for mild Type I and Type II reaction 
cases. This regime was not effective for severe cases of reactions 
especially Type II reactions. This correlated with the finding of our study.  
The histopathological features correlated well with the clinical 
findings. The clinical presentation of erythematous, tender plaques of 
Type I reaction correlated histologicaly with epitheloid granuloma 
extending up to the epidermis and dermal edema in 75% of the patients. 
An increase in the number of lymphocytes and multinucleate giant cells 
was also observed. This has also been reported by Ridley DS and Radia 
KB108. Foci of fibrinoid necrosis and destruction of the appendages were 
also seen in 75% of patients. This observation has also been made by 
Ridley DS109. Epidermal changes were seen in 40% of the patients, with 
62.5% of them having an epitheloid granuloma eroding into the 
epidermis. This correlated clinically in those patients with severe form of 
reaction with erythematous plaque and pain over the lesions.  Edema in 
the dermis with hazy collagen fibers were seen only in 75% of the cases 
which probably may be because of use of steroids in these patients prior 
to biopsy. In patients with downgrading reaction, lymphocytes admixed 
with macrophages were seen. Ridley and Radia108 have reported 
increased numbers of macrophages and bacilli in histopathology sections 
of patients with downgrading reaction. This is similar to the findings of 
our study. In patients with Type II reaction, all patients had neutrophilic 
infiltration of the dermis overlying foci of foamy macrophages. Dermal 
edema and grenz zone were observed in 80% of the cases. In most of the 
patients, neutrophilic abscesses, panniculitis and vasculitis were 
observed. As reported by Vinod Kumar Sharma110 polymorphonuclear 
invasion of the vessel wall is a characteristic finding110in ENL. Our study 
has confirmed this finding. 
Some other interesting findings were noted in our study. One 
patient was initially diagnosed as a case of BB down grading to BL 
Hansen’s disease. He later developed ENL and required systemic steroids 
for a period of one year. After a year of quiescence, he developed late 
reversal reaction. One patient who was diagnosed with histoid Hansen’s 
disease subsequently developed ENL about 3 years after initiation of 
MDT. We had another patient with Histoid Hansen’s disease, who also 
went on to develop ENL 3 months after initiation of MDT. One patient 
presented with ENL as the first manifestation of leprosy. 
 
CONCLUSION 
1. The majority of the patients seen in either reaction were in the 21- 
40 years age group which corresponds to the highest age incidence of 
both Type I and Type II lepra reactions noted in other studies. There was 
an increased incidence of reactions in male patients constituting 68% of 
the total number of cases. The sex ratio observed was 2.1. This high 
incidence in males could probably be due to increased tendency of males 
to seek prompt medical attention. The mean age of patients with Type I 
reaction was 39.8 years and the sex ratio 1.3. The mean age of patients 
with Type II reaction was 37.5 years and the sex ratio 4.0. The high 
incidence of Type I and Type II reactions in 21 -40 years reflects the high 
incidence of leprosy in this age group. 
2. Most of the patients with Type I reaction had borderline 
tuberculoid leprosy. Even though most of the patients who developed 
type II reaction were primarily diagnosed with lepromatous leprosy, there 
were three patients with histoid leprosy who went in for ENL. An 
increasing trend of patients with histoid leprosy developing ENL has been 
found in this study. Studying a larger sample size may further confirm 
this finding. Type III reaction was not seen in any of the patients. 
3. Among the patients with Type I reaction, a great proportion of 
them developed the reaction de novo, next to which most of them 
developed the reaction 1-3 years after initiation of MDT. Most of the 
patients with Type II reaction (60%) presented between 1 -5 years 
following diagnosis and treatment. A tendency for ENL to present de 
novo has also been found in this study. Type I reaction occurring de novo 
is a cause for concern as this can result in neuritis and deformity. Two 
patients presented with ENL de novo (one lepromatous and the other 
borderline lepromatous). This calls for need to improve the surveillance 
for early detection and prompt treatment of the disease as it affects both 
the individual and the society in spread of the disease. 
4. Neuritis (predominantly ulnar neuritis) was the predominant 
feature in addition to raised erythematous skin lesions in Type I reaction. 
Newer deformities occurring during the reactional episodes were seen in 
20% of the cases, which is quite significant. This increased incidence of 
neuritis demands early intervention and prompt treatment to avoid 
deformities and improvement in the quality of life of the patients . In 
patients with Type II reaction, fever, arthralgia, edema of extremities, 
neuritis and lymphadenitis were the predominant features noted. Iritis and 
orchitis were seen in patients with severe Type II reaction. So it is 
imperative to look for these findings in patients to initiate early treatment 
and prevent catastrophic consequences. Patients with moderate and 
severe Type I and Type II reaction were found to require steroids for 
prolonged periods. 
5. The clinical features of patients with both Type I and Type II 
reactions correlated well with the histopathological findings. The clinical 
severity of Type I reaction correlated histopathologically with the degree 
of dermal edema. Patients with severe ENL reaction were found to have 
neutrophilic infiltrates, neutrophilic abscess, panniculitis and vasculitis on 
histopathological examination. 
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Parthasarathy                           
                           
                           
40 M BLHD/ENL
Started 
with R + - - - - + - - - - - - - mod √  + 3+ + - + + - - - + +
Shravan 23 M LLHD/ENL
Started 
with R  +  >102° F + + + + + - - + - - - - severe √  + 3+ + + + - + + + + +
Prakash 25 M LLHD/ENL 3yrs <102° F - + + - - - - - - - - - mod √  - 
-
ve + + + - + + + + +
Bhagwan Das 62 M HHD/ENL 3-5yrs <100° F + - - - - - - - - - - - mod √  +           5+ - - - + - - - - +
Kathavarayan                             
                             
                             
                           
                             
                           
55 M LLHD/ENL 4 months >102° F + + + + + + - - - - - - severe √  + 4+ + + + + - + - - +
Selvam 15 M HHD/ENL 3 months 100-102°F - + + + - - - - - - - - mod √  + 5+ - - - + - - - - -
Mani 37 M LLHD/ENL 1-3yrs 100-102°F + + - - - - - + - - - + severe √  + 4+ + - + - + + + + +
Venkatesh 38 M LLHD/ENL 3-5yrs 100-102°F - + - - + - - - - - - - mod √  + 
-
ve - + - + - - - - -
Kadirvel 60 M
Relapse 
LLHD/ENL 1-3yrs 100-102°F - + + - + - - - - - - - mod −  - 5+ - + + + - - - - -
Parthiban 25 M
Old 
LLHD/ENL 3-5yrs >102° F + + + - - - - + + - - - severe √  + 1+ + + + - + + + + +
Chelladurai                            51 M
Old 
BLHD/ENL 1-3yrs <100° F + + - + + - - - - - - - mod − √ + 
-
ve + + + - + + + + +
Padmanaban                             35 M
Relapse 
LLHD/ENL 1-3yrs >102° F + + + + - - + + - - - + severe √  + 5+ + + + - + + + + +
Deenadayalan                            
                             
                             
                              
                              
45 M
Old 
BLHD/ENL 3-5yrs <100° F - - - - - - - - - - - - mod −  - 
-
ve + + + + - + - - +
Rajendran 40 M
Old 
LLHD/ENL 3-5yrs <100° F + + - + - - - - - - - - mod −  - 4+ + + - - + - + - +
Yagesh 27 M
Old 
LLHD/ENL 3-5yrs 100-102°F + + - + + + - + + - + - mod  √ - 3+ + + + - + + + + +
Venkatesh 24 M
Old 
LLHD/ENL >5yrs 100-102°F + + - - + - - - - - - - mod  - - 2+ + + + + - - - - -
Suseela 40 F
Relapse 
LLHD/ENL 4 months 100-102°F + + - - - - - + - - - - mod  √ + 5+ + + + - + - + - +
Jeyalakshmi                             
                              
               
35 F
Old 
HHD/ENL 5yrs 100-102°F + + - - + - - + - - - - mod  - -
-
ve - + + - + + + + +
Devi 42 F
Old 
LLHD/ENL 1-3yrs 100-102°F + + - - - - - + - - - - severe  √ + 5+ + + + + - - - + +
Kumari 40 F
Old 
LLHD/ENL 5 months >102° F + + - + + - - - - - - - severe  √ - 2+ + + + + - - - - +
Gurumoorthy                        
                        
        
        
        
        
29 M
BTHD/ 
TYPE I  
Started 
with R - - + - - - - - + + - - - severe √ - 
-
Ve + - +
Epitheloid 
granuloma   - 
Sunitha 30 F
BTHD/ 
TYPE I  
Started 
with R - - + - - - - - + + - - - severe - − - 
-
Ve + - +
Epitheloid 
granuloma   - 
Rani 40 F
BLHD/ 
TYPE I 1-3yrs - - - - - - - - - - - - - mod √  + 
-
Ve - - -
Epitheloid 
granuloma   - 
Rukmani 55 F
BTHD/ 
TYPE I  2 months - - - - - - - - - - - - - mod -  - 
-
Ve - - +
Epitheloid 





with R - - - - - - - - - - - - - mod - − - 1+ +  - 
Epitheloid 
granuloma + 
macrophages   - 
Sumathy 15 F
Old BTHD/ 
TYPE I 3-5yrs - - - - - - - - - - - - - mod - − - 
-
Ve - - -
Epitheloid 
granuloma   - 
Senjurammal     
      
     
     
60 F
Old BTHD/ 
TYPE I 3-5yrs - - - - - - - - - - - - - mod - − - 
-
Ve +  + 
Epitheloid 
granuloma    
Sunitha 32 F
BTHD/ 
TYPE I  8 months - - + - - - - - + - - - - severe - − - 
-
Ve +  + 
Epitheloid 
granuloma   
Shanthi 30 F
BTHD/ 
TYPE I  1-3yrs + - - + - - - - + - - - - severe - √ + 
-
Ve - - - 
Epitheloid 
granuloma   - 
Saradha 54 F
BTHD/ 
TYPE I  2-5yrs + - + - - - - - + - - - - mod √  + 
-
Ve +  + 
Epitheloid 
granuloma   - 
Yadhambal     45 F
Old BTHD/ 
TYPE I 3-5yrs - - + - - - - - + - - - - severe √  - 
-
Ve +  + 
Epitheloid 
granuloma   - 
Muniammal     61 F
BTHD/ 
TYPE I  11 months - - - - - - - - + - - - - mod  √ - 
-
Ve -  + 
Epitheloid 
granuloma   - 
Karpagam     
     
     
     
                         
     
     
          
     
49 F
BTHD/ 
TYPE I  
Started 
with R + - - + - - - - + - - - - severe √  - 
-
Ve - - + 
Epitheloid 
granuloma   - 
Vijaya 35 F
BTHD/ 
TYPE I  1 month - - - - - - - - - - - - - mod  √ - 
-
Ve +  + 
Epitheloid 
granuloma   - 
Arun 18 M
BTHD/ 
TYPE I  
Started 
with R - - - - - - - - - - - - - mod - - - 
-
Ve -  + 
Epitheloid 
granuloma   - 
Pasupathy 51 M
Old BTHD/ 
TYPE I 1-3yrs - - - - - - - - - - - - - mod - - - 
-
Ve +  + 
Epitheloid 




TYPE I 5 months - - - - - - - - - - - - - mod - - -
-
Ve -  + 
Epitheloid 





with R - - - - - - - - - - - - - mod - - - 1+ -  + 
Epitheloid 
granuloma   - 
Nagiah 55 M
BTHD/ 
TYPE I  
Started 
with R - - - - - - - - - - - - - mod - - - 1+ -  + 
Epitheloid 
granuloma   - 
Vijay 16 M
BTHD/ 
TYPE I  
Started 
with R + - + - - - - - + + + − - severe - - -
-
Ve - - + 
Epitheloid 
granuloma   - 
Velusamy 62 M
Old BTHD/ 
TYPE I 1-3yrs - - - - - - - - - - - - - mod  - - 
-
Ve - - - 
Epitheloid 
granuloma   - 
Adamshariff     
     
                     
     
24 M
BTHD/ 
TYPE I  >5yrs - - - - - - - - - - - - - mod  - - 
-
Ve - - + 
Epitheloid 
granuloma   - 
Pethi 43 M
Old BTHD/ 
TYPE I 1-3yrs - - -  - - - - - - - - - mod - - - 
-
Ve - - + 
Epitheloid 
granuloma   - 
Pintu 21 M
Old BTHD/ 
TYPE I 1-3yrs + - + - - - - - + + - - - severe - √ + 
-
Ve + - + 
Epitheloid 
granuloma   - 
Gopal 45 M
BTHD/ 
TYPE I  
Started 
with R - - - - - - - - - - - - - mod  - - 
-
Ve - - + 
Epitheloid 
granuloma   - 
Kumar   -     34 M
BTHD/ 
TYPE I  
Started 
with R - - -  - - - - - - - - mod √ - +
-
Ve - - + 
Epitheloid 
granuloma   - 
Karuppasamy 49 M                   
BTHD/ 
TYPE I  
Started 
with R - + - - - - - - + + - - - severe √ + 
-
Ve + - + 
Epitheloid 
granuloma   - 




with R - - + - - - - - + - - - - mod  - - 
-
Ve - - - 
Epitheloid 
granuloma + 
macrophages     - 
Velayudham     
     
31 M
Old BTHD/ 
TYPE I 11 months - - -  - - - - + - - - - mod  √ + 
-
Ve + - - 
Epitheloid 
granuloma   - 
Ganesan 32 M
BTHD/ 
TYPE I  1-3yrs - - + - - - - - + - - - - mod  √  
-
Ve - - - 
Epitheloid 
granuloma   - 
 

KEY TO MASTER CHART 
OH  - Oedema of hands 
OF  - Oedema of feet 
Lym  - Lymphadenitis 
Epi  - Epistaxis 
Orch  - Orchitis 
Iri  - Iritis 
Neu  - Neuritis 
CH  - Claw hand 
FD  - Foot drop 
UL  - Ulceration of Skin lesions 
Exacer  - Exacerbation 
Rph Exacer - Repeated Exacerbations 
BI  - Bacteriological Index 
Epi changes - Epidermal Changes 
GZ  - Grenz zone 
Inf.D  - Infiltrate in dermis 
Inf D+S - Infiltrate in dermis & subatis 
N.A  - Neutrophilic abscers 
Panni  - Panniculitis 
Vascu  - Vasculitis 
REACTIONS IN LEPROSY CASE SHEET 
 
 




PRESENTING COMPLIANT  
 
1. Skin Lesions  : Anaesthetic / Hypoanaesthetic / Normoesthetic 
 
 






2. Numbness  
 





3. Painful nodules  
 








 Site      Duration 
 
Hands / feet 
 





5. Weakness / Paralysis 
 
 Site      Duration 
  
a) Upper Limb 
b) Lower Limb 
c) Others 
 
6. Deformity  
 






II.H/O PRESENTING ILLNESS 
 
  Onset & Duration: 
 
  Progress  
 
  Initial - 
 
  Late  -   
 
 H/O Fever       Y / N 
 H/O  Swollen feet / hands     Y / N 
 H/O  Ulceration of the lesions / elsewhere   Y / N 
 H/O  Nasal stuffiness       Y / N 
 H/O  Epistaxis       Y / N 
 
 Concurrent infections / illnesses 
 
    URI / LRI    Y / N 
    UTI     Y / N 
    Pain Abd    Y / N 
    AGE     Y / N 
 
H / O Surgery        Y / N 
 
Emotional / Physical Stress       Y / N 
III CONTACT HISTORY 
 
  Present / Absent  
 
IV TREATMENT HISTORY 
 
  Treatment started on: 
   
Regime followed : 
   
Other drugs given 
   
Regular / Defaulter / Dropout 
 
G / E 
 
  Built  : Ill / Mod / Well 
 
  Nairishment : Ill / Mod / Well 
 
  Anemia : Present / Absent 
  
  Jaundice : Present / Absent 
 
  Fever  : Present / Absent 
 
  Clubbing : Present / Absent 
 
  Pedal edema : Present / Absent 
 
  Lymphadeno : Gen   : Present / Absent 
  pathy 
     Regional : Present / Absent 
      
     Site  : 
 
   
Joint Swelling : 
 
  Hepatosplenomegaly : 
 
  Orchitis : 
 
D / E 
 












F)Type of Lesion :  Macule / Patch / Papule / Plaque / nodule / infiltration/ Ichthyosis 
 Face     
  
  
Trunk    : Ant 
      Post 
 
  
Gluteal region : 
 
 
Upper limbs : Arm 
  Forearm 
     Hands 
    
 
  
Lower Limbs : Thigh 
     Legs 









G) Colour of the Lesion : HP/Erythematous / Normopigmented/copper coloured /scar 
 
 Face :  
 
  
Trunk : Ant 
   Post 
 
  
Gluteal  region : 
 
  
UL : Arm 
   Forearm 
   Hands 
 
  
LL : Thigh 
   Leg 




h) Surface of Lesion :  Normal / Dry & Wrinkled / Succulent/ Scarred / Scaly  
 
 
Face :       
        
  
Trunk  : Ant  





   
  
UL : Arm 
  Forearm 
   Hands 
 
     
LL : Thigh 
Leg 
   Foot  
 
i) Sensation of lesion : Tm-T-P- Present / Diminished / Absent 
 
 Face   :       
 
  
 Trunk  : Ant  
   Post 
 
 Gluteal region 
 
   Arm 
 UL : Ra 
   Hands 
 
   Thighs 
 LL : Legs 
   Foot  
 
PERIPHERAL NERVES : 
 
  GA SO ST UN RCN RAD MED LPN SUR PTN SP 
  L   R  L   R   L     R   L     R   L    R    L   R   L     R  L    R   L     R  L    R   L   













SENSATION OF EXTREMITIES: 
a. Corneal sensation    L Present / Diminished / Absent 
     R Present / Diminished / Absent 
 
 
b. Face     L Present / Diminished / Absent 
     R Present / Diminished / Absent 
 
c. Palms    L Present / Diminished / Absent 
     R Present / Diminished / Absent 
 
d. Soles    L  Present / Diminished / Absent 



















































































EXTENSORS OF  
        DIGITS
TIBIALIS 
ANTERIOR 






a. Face:  Lagophthalmos     Right/ Left 
Facial       Right/ Left 
 
 
b. Hands:  Ulnar claw                                      Right/ Left 
Ulnar median claw    Right/ Left 
Wrist drop       Right/ Left 
Ape thumb      Right/ Left 
Wasting thenar     Right/ Left 
Wasting hypothenar     Right/ Left 
Wasting lumbricals     Right/ Left 
Deviations fingers / toes    Right/ Left 
Resorption fingertips     Right/ Left 
Resorption toe tips     Right/ Left 
Swan neck       Right/ Left 
Hooding      Right/ Left 
 
 
         
c. Feet:   Foot drop     Right/ Left 
Claw toes      Right/ Left 
Toe drop      Right/ Left 
 
d. Lepromatous leprosy:   
Ear lobe thickening    Right/ Left 
 
e. Glove and stocking anaesthesia: 
Right upper limb      Present/ Absent 
Left upper limb       Present/ Absent 
Right lower limb    Present/ Absent 
Left lower limb     Present/ Absent 
Depression of nose     Present/ Absent 
Loss of incisors     Present/ Absent 
Hoarseness of voice      Present/ Absent 
Gynaecomastia / -thelia   Present/ Absent 
Infiltration of face     Present/ Absent 
 
ULCERS 
FEET      Present/ Absent 




 BLOOD TC 
   DC 
   ESR 
   HB 
   Bl. SUGAR 
   Bl. UREA 
   S. CREATININE 
  
 LIVER FUNCTION TEST 
   S. T. PROTEIN 
    
S. BILIRUBIN 
   SGOT 
   SGPT 
   SAP 
  







SMEAR FOR MP/ MF 
 
 VDRL   
 
 HIV Ab 
 
  
X-RAY CHEST PA VIEW 
 
  
















DATE   CLINICAL PROGRESS     TREATMENT 
